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Introduction to Thesis 
 
Background 
 
Introduction 
Antidepressant medications that modulate the levels of brain monoamine neurotransmitters, 
including serotonin, noradrenaline and dopamine, have been used for over half a century to 
treat affective disorders. Yet there is limited understanding of how monoamine dysregulation 
gives rise to the cognitive features of depression or how these medications exert their 
therapeutic effects at a cognitive level. Furthermore, the fact that up to 70% of patients 
treated with these medications fail to respond adequately remains a significant challenge in 
the management of these disorders (Joanna and Irving, 2005; Souery et al.  1999). There is 
evidence that this response may be genetically determined and over the last decade, a variety 
of studies have begun to explore the pharmacogenomics of antidepressant response (Kato and 
Serretti, 2010). Yet significant advances in this area have thus far been limited by a failure to 
produce a consistent pattern of results. 
 
Cognitive models of affective disorders indicate that biased processing of emotional 
information plays a role in the aetiology and maintenance of symptoms (Leppanen, 2006) and 
more recent  evidence suggests that at least one of the mechanisms by which antidepressant 
medications exert their therapeutic effects is by modulating emotional processing (Harmer, 
2008). However, it is also increasingly recognised that inter-individual variation in responses 
to emotional stimuli may contribute not only to differences in vulnerability (and resilience) to 
emotional disorders, but also response to therapeutic agents (Hamann and Canli, 2004). Yet 
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the neurobiological mechanisms that underlie these individual differences are still not fully 
understood. It is increasingly accepted that genetic factors explain small but significant 
amounts of this variability and evidence to date suggests that variation in a number of genes 
involved in the regulation of central monoamine levels may contribute (Todd et al.  2011). 
Thus, emotional processing may be a mediating factor in the relationship between genetic 
variation and antidepressant response. Improved understanding of the genetics of emotional 
processing is therefore likely to contribute to enhanced understanding of individual variation 
in antidepressant response. Genes involved monoaminergic signalling represent suitable 
candidates for further investigation of the relationship between the genetics of emotional 
processing and antidepressant response.  
 
Emotional processing 
For a given organism, emotions comprise a collective change in body and brain states in 
response to the evaluation of particular events with respect to their significance, i.e., 
importance for survival. Emotional processes can therefore be considered to include the 
cognitive processes by which an organism judges and represents the value of internal or 
external stimuli and responds accordingly. Thus, emotional processing also relates to the 
cognitive processes of perception, attention and reasoning, forming  the basis for learning in 
animals and humans. Attention refers to the process of selectively concentrating on one 
aspect of the environment while ignoring other things1 (Anderson, 2004) whilst perception 
has been defined as the cognitive process by which organisms interpret and organise 
sensation to produce a meaningful experience of the world (Lindsay and Norman, 1977).. 
Perceptual organisation and interpretation of sensory information follows the process of 
attaining awareness and involves the additional processes of judgement or evaluation 
                                                 
1
 This definition relates to selective attentional processes. 
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(Adolphs, 2003). Hence, attentional processes may be considered to support perception. The 
predominant framework utilised in the investigation of emotional processing is a two 
dimensional model that suggests that stimuli range from negative (unpleasant or aversive) to 
positive (pleasant or appetitive) along a dimension of valence and from calm (dull) to 
arousing (exciting) along an arousal dimension (Lang et al.  1993). This framework has been 
utilised in a series of studies that demonstrate preferential (or biased) attention to, and 
perception of, emotionally salient stimuli in healthy individuals (Anderson, 2005; Anderson 
and Phelps, 2001; Keil and Ihssen, 2004; Richards and Blanchette, 2004)  
 
Furthermore, emotional experiences are more likely to be remembered than non-emotional 
ones (Brown and Kulik, 1977). This memory bias for emotional information, termed 
‘emotional memory’, has been demonstrated experimentally in healthy human volunteers 
using a variety of stimuli including words, pictures, narrated slide shows and film clips 
(Bradley et al.  1992; Heuer and Riesberg, 1990; LaBar and Phelps, 1998; Williams et al.  
1996). It was initially suggested that this memory bias was entirely consequent to enhanced 
attentional processing (Easterbrook, 1959). However, this view has since been challenged by 
behavioural experiments that demonstrated that enhanced memory for emotional events does 
not occur solely because more attention is devoted to the emotional information during 
encoding, the initial stage of memory formation (Christianson et al.  1991). More recent 
evidence from pharmacological and functional neuroimaging studies in healthy humans has 
shown that such memory biases are likely to arise due to the effect of emotional arousal on 
the process of memory consolidation,  the process by which encoded memories become 
stable over time (McGaugh, 2000). This evidence also suggests that these biases are mediated 
by the arousal characteristics of the stimuli as opposed to valence per se. 
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Emotional processing and affective disorders 
Early behavioural studies of emotional processing in depression tended to focus on emotion 
perception (or recognition) and reported a general deficit in the ability to accurately label 
facial emotional expressions in symptomatic patients compared to healthy controls (Persad 
and Polivy, 1993; Rubinow and Post, 1992). Other studies suggested that sadness was most 
often correctly recognised in depression and difficulties in recognition may at least in part be 
due to a tendency to label any unidentified emotion as sadness (Mandal and Bhattacharya, 
1985). Subsequent behavioural studies also examined attentional processes using a wider 
range of emotional stimuli including words and pictures and have demonstrated a consistent 
exaggerated attentional bias towards negative compared to neutral stimuli in depressed 
patients compared to healthy participants (Gotlib et al.  2004b; Gotlib et al.  2004a). The 
picture in remitted patients has been less clear with some initial studies failing to find any 
difference between healthy participants and euthymic patients (Addington and Addington, 
1998; Edwards et al.  2001; Lembke and Ketter, 2002). However more recent studies have 
suggested that emotional processing abnormalities persist following remission of acute 
depressive episodes, thus representing trait markers of the disorder (Bozikas et al.  2006; 
McClure et al.  2005; Yurgelun-Todd et al.  2000).  
 
Studies of emotional memory  in affective disorders, predominantly depression have largely 
focussed on two main phenomena: state-dependence and mood-congruence (Blaney, 1986). 
The former refers to the notion that what is remembered during a given mood is at least partly 
determined by what was learned when previously in that mood. State-dependence thus differs 
from the usual conceptualisation of emotional memory in that the affective properties of the 
learned material itself are considered irrelevant. Mood-congruence, on the other hand, implies 
that some material, by virtue of its affective valence, is more likely to be encoded or retrieved 
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when congruent with the prevailing mood. This phenomenon also differs from typical 
conceptualisations of emotional memory, in that it is valence specific, independent of arousal 
and is dependent on factors other than the stimulus itself. The phenomenon of mood-
congruence has been extensively investigated in depressive disorders and several studies have 
demonstrated that despite overall impaired memory, depressed patients show a bias towards 
enhanced recognition and recall of negatively valenced information compared to healthy 
volunteers (Murphy and Sahakian, 2001). By contrast,  memory for positive information is 
reported to be impaired relative to negative and neutral information (Burt et al.  1995; Matt et 
al.  1992).  Thus, contemporary cognitive models of depression emphasise a systematic 
negative attentional and recall bias however such models have only recently begun to 
integrate underlying neurobiological mechanisms including neurochemistry and genetics 
(Beck, 2008). 
 
The neuropharmacology of emotional processing 
These cognitive-behavioural findings have led to interest in the effect of antidepressant 
medications on emotional processing. One fruitful approach to developing this understanding 
has been the investigation of the effect of such medications on emotional processing in 
healthy volunteers. However, whilst this constitutes a relatively recent approach to 
understanding the basic mechanisms of therapeutic agents, it has been used for nearly two 
decades in the domain of cognitive and affective neuroscience to delineate the 
neurochemistry of human emotional processing. This literature has focussed on the role of the 
catecholamines (dopamine and noradrenaline) in emotional memory biases. For example, the 
central role of noradrenaline in emotional memory was confirmed in a seminal study 
demonstrating the attenuation of emotional memory following the administration of the beta 
blocker propanolol to healthy volunteers (Cahill et al.  1994). Further studies confirmed that 
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this occurred via central, as opposed to peripheral, mechanisms (van Stegeren et al.  1998) 
and long-term consolidation, rather than encoding, processes (van Stegeren et al.  2005). 
Much of the evidence linking dopamine and emotional processing derives from studies 
conducted in animals (Greba et al.  2001; Greba and Kokkinidis, 2000; Guarraci et al.  1999; 
Guarraci et al.  2000; LaLumiere et al.  2003; LaLumiere et al.  2004). However, a number of 
recent studies, including work done in our laboratory demonstrates that dopamine is likely to 
play a similar role in human emotional processing (Takahashi et al.  2005; Takahashi et al.  
2010; Tessitore et al.  2002) (Gibbs et al.  2007).  Crucially, the vast majority of 
pharmacological studies have demonstrated similar effects of dopaminergic manipulation on 
memory for both positive and negative emotional information. Whilst the pharmacology of 
attentional biases for emotional information has been less extensively researched, at least two 
recent studies conducted in healthy volunteers also suggest a role for both noradrenaline and 
dopamine in the modulation of such biases (De Martino et al.  2008a; Franken et al.  2004). 
 
In contrast to the affective neuroscience literature aimed at elucidating the neurobiological 
mechanisms of emotional processing and focussing on the role of the catecholamines 
dopamine and noradrenaline in memory, interest in serotonergic mechanisms contributing to 
human emotional processing has evolved more from experimental medicine approaches 
aimed at understanding the cognitive mechanisms of antidepressant drug effects.  Over the 
last decade, the ability of both serotonergic and noradrenergic antidepressant drugs to 
produce biases towards positive information has been documented in studies of emotional 
processing in healthy individuals (Harmer et al.  2008; Harmer et al.  2003; Harmer et al.  
2004; Murphy et al.  2009a; Norbury et al.  2007). Yet, it is worth noting that one study 
demonstrated enhanced attention processing of both positive and negative stimuli following 
administration of a single dose of the noaradrenergic antidepressant reboxetine (De Martino 
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et al.  2008b; Murphy et al.  2009b). Furthermore, other studies have found that single doses 
of the serotonergic antidepressant citalopram enhanced fear processing (Browning et al.  
2007). It has been suggested these seemingly inconsistent findings may relate to dissociable 
effects of single versus chronic dosing (Harmer et al.  2009). Indeed, evidence from both 
animal and human studies that acute doses result in an initial enhancement in the processing 
of negative information that is attenuated with repeated dosing (Burghardt et al.  2004; 
Harmer et al.  2003; Harmer et al.  2004). 
 
The genetics of emotional processing 
Given the central role of monoamine neurotransmitters (serotonin, dopamine and 
noradrenaline) in emotional processing as detailed above, efforts to understand 
neurobiological mechanisms underlying individual differences in emotional processing have 
focussed on variations in genes involved in monaminergic signalling.   
 
Psychotropic agents targeting the serotonergic system play a central role in the treatment of 
affective spectrum disorders and are known to modulate emotional processing as described 
above. Therefore unsurprisingly, one of the genetic variants that have been most extensively 
investigated in relation to human emotional processing and emotional disorders is the gene 
encoding the serotonin transporter (5-HTT). An insertion/deletion polymorphism (5-
HTTLPR) in the gene promoter region results in two common allelic variants: short (S) and 
long (L). The former has been associated with reduced transporter transcription, resulting in 
approximately 50% reduction in transporter availability in vitro and presumed increased 
synaptic serotonin availability (Heils et al.  1996). The S allele has been associated with 
anxiety-related personality traits that are related to an increased risk for depression (Hariri et 
al.  2005; Pezawas et al.  2005; Schinka et al.  2004). This polymorphism has also been 
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associated with differential reactivity of the amygdala, a key brain structure involved in the 
processing of emotional information. In healthy individuals, the s allele has been associated 
with increased amygdala responsivity to emotional stimuli compared with the l allele (Hariri 
et al.  2002; Hariri et al.  2005; Heinz et al.  2004) (Canli et al.  2005). However, whilst these 
studies have confirmed genotype dependent difference in brain activation during emotional 
processing, they failed to find any differences in cognitive-behavioural measures. Indeed, it 
has been suggested that functional neuroimaging studies have greater statistical power to 
detect genotype dependent effects as they are considered to represent a more proximate 
biological link to genes (Hariri et al.  2006). Therefore, whilst the sample sizes may have 
been appropriate for detecting such neural differences, it is likely that the detection of 
behavioural differences would have required much larger numbers. Therefore the behavioural 
implications of these neural markers remained unclear. Recent studies investigating the 
potential genetic contribution to attentional biases for emotional stimuli have reported 
behavioural data suggesting an association between 5-HTTLPR variants attentional biases for 
emotional stimuli, however this work also remains in the early stages of development 
(Beevers et al.  2007; Beevers et al.  2009; Beevers et al.  2010; Beevers et al.  2011; Osinsky 
et al.  2008). 
 
The contribution of genetically influenced differences in noradrenergic tone to inter-
individual variation in human emotional processing and disorders has been little explored. A 
common variant of the α2b-adrenergic receptor gene (ADRA2B) involves the deletion of 
three glutamic acid residues in the third intracellular loop region (Small et al.  2001). This 
deletion variant is common across ethnic groups but has been found to be more prevalent in 
Caucasians (31%) compared to African-Americans (12%). It is associated with two 
potentially relevant phenotypic changes, relative to the insertion wild-type: (i) a loss of 
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agonist-promoted desensitization and (ii) a moderate decrease in agonist-mediated receptor 
function. Thus, its functional consequences, which are still not fully understood, may be 
related to either of these changes. The functional implications are further complicated by the 
pre-synaptic and post-synaptic location of the (auto)receptor whereby activation may lead to 
both potentiation or attenuation of noradrenergic transmission, respectively. However recent 
evidence suggests that the ADRA2B deletion variant acts primarily as a loss of function 
polymorphism, resulting in a reduction in the activity of the α2b-adrenergic autoreceptor, 
leading to potentiation of noradrenergic transmission in an autosomal dominant manner 
(Rasch et al.  2009). A prior study involving a large sample of healthy Swiss volunteers and 
survivors of the Rwandan genocide, found that the ADRA2B deletion variant was associated 
with significantly greater emotional enhancement of memory in both groups, as well as 
increased PTSD-related experiences in the genocide survivors (de Quervain et al.  2007). 
Further studies have demonstrated an association between the ADRA2B deletion variant and 
increased amygdala activation in response to emotional relative to neutral stimuli (Cousijn et 
al.  2010; Urner et al.  2011).  
 
Dopaminergic transmission has played a less central role in the therapeutics of affective 
spectrum disorders. However, the majority of effective antidepressants display either primary 
(in the case of the atypical antidepressant bupropion) or secondary dopaminergic effects. 
Evidence has emerged linking variation in the catecholamine-O-methyltransferase enzyme 
(COMT) gene, responsible for the degradation of dopamine in the prefrontal cortex to 
emotional processing. This more recent evidence has emerged as a adjunct to the more 
extensive body of work linking COMT to cognitive processing (Barnett et al.  2008). A 
single nucleotide polymorphism (SNP) (val158met) that results in the substitution of the 
amino acid methionine (met) for valine (val) causes a 25 to 75% reduction in the activity of 
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the COMT enzyme (Chen et al.  2004), leading to increased levels of extracellular dopamine 
in the prefrontal cortex (PFC) and enhanced performance on PFC cognitive tasks including 
working and episodic memory (de Frias et al.  2004; Egan et al.  2001). However, evidence 
has also emerged suggesting that this polymorphism may also play a role in emotional 
processing. For instance, a number of functional neuroimaging studies have demonstrated 
exaggerated neural responses to negative but not positive emotional stimuli in  COMT 
met158 carriers (Smolka et al.  2005). In fact, in the former study, the number of met alleles 
was shown to positively correlate to increased amygdala activation for unpleasant negative 
stimuli. Other behavioural genetics studies examining the role of COMT genetic variation in 
fear processing using affective startle reflex modulation tasks have also demonstrated that 
met/met carriers display an exaggerated reaction towards aversive stimuli compare to val/val 
carriers (Montag et al.  2008). Therefore whilst the met allele may be advantageous for 
cognitive processing, the val allele is advantageous for emotional processing and may 
possibly confer a resilience to emotional disorders (Heinz and Smolka, 2006). It has been 
suggested that these pleiotropic effects may be of evolutionary significance, thus contributing 
to the relatively equal prevalence of both alleles within populations (Mier et al.  2009).  
 
The enzyme monoamine oxidase A (MAOA) is involved in the degradation of all three 
monoamines (noradrenaline, dopamine and serotonin and therefore also plays a critical role 
in the regulation of their neurotransmission. A variable number of tandem repeats (VNTR) 
polymorphism gene coding for MAOA selectively influences the transcriptional activity of 
the MAOA gene promoter such that enzyme expression is relatively high for carriers of the 
3.5-repeat or 4-repeat alleles (MAOA H) and lower for carriers of 2, 3, or 5 repeats (MAOA 
L). Thus MAOA L individuals are predicted to have higher brain monoamine levels and this 
has been linked to increased amygdala activation in healthy individuals during processing of 
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unpleasant stimuli, compared to the high expression (MAOA H) genotype (Lee and Ham, 
2008; Meyer-Lindenberg et al.  2006). A further study has also confirmed links between this 
polymorphism and emotional neural correlates of processing in the normal population 
(Williams et al.  2009). However, none has reported any cognitive/behavioural measures of 
emotional processing. 
 
Scope 
 
Rationale 
Despite significant advances in the integration of cognitive and neurobiological models of 
emotional processing, as described above, understanding of the genetic determinants of inter-
individual variation remains rudimentary. For example, behavioural genetics studies have 
tended to focus on the effects of single genes within a given study/sample and although they 
are generally considered to act synergistically, few studies have specifically investigated 
interactions between these polymorphisms. However, it has been suggested that gene-gene 
interactions (or epistasis) are likely to be of greater importance in predicting effects, 
particularly in complex traits and disorders (Elvevåg and Weinberger, 2009). Consequently, 
important effects might be missed if the genes are examined in isolation without allowing for 
potential interactions with other known or unknown genes or environmental factors. This 
may account for some of the inconsistencies in single-gene association studies including non-
replication of findings.  
 
Thus, whilst the evidence to date suggests that the genes involved in monaminergic 
neurotransmission (5-HTTLPR, ADRA2B, MAOA and COMT) may contribute to an 
increased risk of affective disorders via their effects on emotional processing, little is known 
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about how the different variants of these genes might interact within a given individual to 
influence these outcomes. Given the interactive relationships between these neurotransmitter 
systems in the brain, it is very likely that these genes also interact to produce their effects. In 
fact, such effects have begun to be explored. For example, one of the only recent studies to 
examine multiple gene effects, established that the COMT met158 and 5-HTTLPR S alleles, 
as well as an additional 5-HTTLPR SNP variant (G) allele, produced an additive effect in 
enhancing neural responses to emotional stimuli (Smolka et al.  2007).   
 
The purpose of this thesis was to extend understanding of the impact of genetic variation on 
emotional processing in healthy individuals. Studying healthy volunteers provides the 
opportunity to understand the neurobiology of emotional processing, likely to be relevant to 
therapeutic advances, in the absence of likely confounders in clinical populations such as 
concomitant or previous treatment, the disease process itself, and other factors that may be 
subject to increased variability in a patient population, such as intelligence and motivation 
(Gilles and Luthringer, 2007). Given that attention and memory biases for emotional 
information are a well established feature of emotional processing with known neural 
correlates, these were used as the marker of cognitive performance. The candidate genes of 
interest (COMT, 5-HTTLPR, ADRA2B and MAOA) were selected on the basis of evidence 
of links to behavioural and/or neural correlates of emotional processing based on review of 
the existing literature detailed above. Additionally, given that the brain derived neurotrophic 
factor gene (BDNF) val66met polymorphism has also been suggested as a predictor of 
episodic memory, this genotype will also be determined to ensure that the results are not 
confounded by variation in this gene (Egan et al.  2001). 
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Aims 
The general aim study was to investigate the effects of the candidate genetic polymorphisms 
(COMT met158, 5-HTTLPR S, ADRA2B Del and MAOA L) on cognitive measures of 
emotional processing.  
 
The specific aims were: 
(i) to examine the independent contribution of each polymorphism (single-gene 
effects) 
(ii) to conduct a preliminary exploration of epistasis (gene-gene interactions)   
 
Hypotheses 
Single-gene effects 
The primary hypothesis was that COMT, 5-HTTLPR, ADRA2B and MAOA genotype would 
each exhibit a main effect on attentional and memory biases for emotional information. It was 
predicted that the variants that have been associated with increased amygdala reactivity 
(specifically COMT met158, 5-HTTLPR S, ADRA2B Del and MAOA L) would also be 
associated with increased attentional and memory biases for emotional, relative to neutral 
information. We predicted that these biases would increase with increasing numbers of 
‘emotional bias alleles’ (COMT met158, 5-HTTLPR S, ADRA2B Del and MAOA L).  
 
Gene-gene interactions (epistasis) 
As each of these alleles should independently affect monoamine levels, it was hypothesised 
that epistatic effects would be synergistic, i.e. attentional and memory biases for emotional 
information will be correlated with total number of ‘emotional bias alleles’ (COMT met158, 
5-HTTLPR S, ADRA2B Del and MAOA L).   
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Sample size 
The frequencies of the COMT met158 and 5-HTTLPR S are both in the region of 50% in the 
population to be studied (Egan et al.  2001). Hence the following approximate genotype 
frequencies were expected (val/val, 25%; val/met, 50%; met/met, 25% and L/L, 25%; L/S, 
50%; S/S, 25%), respectively. The prevalence of the deletion variant of ADRA2B is 33% 
(Small et al.  2001) hence we expected 55% of the sample to be deletion carriers (including 
homozygous and heterozygous) and 45% to be non-carriers.  For MAOA, the allele 
frequencies are H (65%) and L (35%) and similar genotype frequencies would be expected in 
the hemizygous male sample.  
 
Based on these allele frequencies, power calculations were conducted based on a 5% level of 
significance. A total sample size of 100 would provide 99% power to detect statistically 
significant main effects of COMT and 5-HTTLPR genotypes, and 75% and 65% power to 
detect statistically significant effects of ADRA2B and MAOA, respectively. There are a 
number of limitations to this power analysis. Firstly, given that the effect sizes were not 
known, an estimated moderate effect size of 0.5 was used. Furthermore, it was not been 
possible to model gene-gene interactions in the power calculations due to the complexity of 
such interactions and the lack of exiting data. Nevertheless, the power analysis indicates that 
the present study design is likely to provide sufficient power to detect the effects of 
individual genes. Examination of gene-gene interactions will therefore be exploratory in the 
first instance, but will form the basis for future study design. 
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Overview of thesis 
Our study led to 3 published articles which form the basis of this thesis. In the first two, we 
report on the genetic variation and memory bias component of the study (Gibbs et al.  2010; 
Naudts et al.  2012a). In the third one, we report on the genetic variation and attention bias 
arm of the study (Naudts et al.  2012b).  Thus, the 3 articles concern different aspects of the 
same study on the same 107 participants, who all participated in the same procedure as 
explained below. Due to subject drop-out and genotyping failure, the sample size in the first 2 
articles was reduced to 97 and to 94 in the 3rd article. 
 
Participants 
Healthy male volunteers of White British ethnicity between the ages of 18 and 352 via the 
Mindsearch database were recruited to the study. Mindsearch is a service that connects 
academic researchers at the King’s College London with healthy volunteers from the general 
public to participate in their research projects. The database is run by an administrator who 
maintains the database, identifies potential volunteers for researchers and undertakes out-
reach activities to involve the local community in research. It is funded by the National 
Institute for Health Research Biomedical Research Centre (NIHR-BRC), as well as by 
making a small charge for researcher using the database, and has over 4,000 volunteer 
members. There is no cost to volunteers to be included in the database and they usually 
receive payment for participation in research.     
 
The narrow age range was chosen to reduce the likelihood of valid associations being 
obscured by age differences and the restriction on ethnicity was to reduce population 
stratification effects. Recruitment was limited to male participants. This gender selection also 
has the advantage of avoiding confounding by the now well-established gender differences in 
                                                 
2
 The 40 stated in Article 2 is a typographical error 
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emotional processing (Cahill, 2006). A database of 318 volunteers meeting these 
requirements was provided by Mindsearch. Eligible participants were contacted for possible 
recruitment to the study. They were further screened to exclude any history of psychiatric or 
neurological disorder using a checklist questionnaire (Appendix I). 107 participants meeting 
the inclusion criteria were recruited to the study, including 7 additional participants beyond 
the planned sample of 100, to compensate for drop-outs.  
 
Procedure 
On arrival, following informed consent, buccal swabs were collected from volunteers for 
external genotyping by KBioscience. Of the 107 samples collected, genetic data were 
successfully obtained for 106 for ADRA2B, 105 for COMT, 96 for 5-HTTLPR and 106 for 
BDNF. Due to technical issues with the PCR for the MAOA assay, this polymorphism was 
excluded from analysis. The National Adult Reading Test (Nelson, 1982) was administered in 
order to obtain an estimate of IQ and the encoding phase of the Emotional Memory (EM) 
Task was administered, followed by the Attentional Blink (AB) Task. Participants returned 1 
week later for the recognition memory phase of the EM task. Seven participants failed to 
return for the recognition memory test. Further details on procedure and methods can be 
found in the articles. 
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Abstract 
 The COMT val158 variant has been associated with impaired cognitive function compared to 
the met158 variant yet gene-gene interactions are not well described. In this study we 
demonstrate an interaction between this COMT polymorphism and a deletion variant of 
ADRA2B, the gene encoding the α2b-adrenergic receptor on episodic memory performance. 
Specifically, carriage of the ADRA2B deletion abolished the relative memory impairment in 
homozygous COMT val158 carriers compared to met158 carriers. 
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Introduction 
Animal studies suggest that memory formation is dependent on noradrenergic modulation of 
the process of long-term potentiation (LTP) in the hippocampus (Straube and Frey, 2003). 
Other work also implicates the dopamine system of the prefrontal cortex in modulating 
memory storage (Williams and Goldman-Rakic, 1995). Enhancement of memory for 
emotionally arousing events in animals and humans has been linked to an increase in central 
noradrenergic transmission, mediated via the amygdala and its projections to the 
hippocampus and other brain regions, such as the dopamine system of the prefrontal cortex 
(Roozendaal et al.  2009). Amygdala lesions in animals have been demonstrated to result in 
an attenuated stress-induced increase in dopamine turnover in the prefrontal cortex (Davis et 
al.  1994). This suggests that the effect of emotional arousal on memory may depend in part, 
on noradrenergic amygdala-influenced effects on the dopamine-related activity of the 
prefrontal cortex. This is supported by functional neuroimaging data highlighting the 
importance of interaction between these brain regions during emotional processing 
(Keightley et al.  2003). More recently, the function of both of these regions has been related 
to genetic variation (Smolka et al.  2005).  
 
A deletion variant of the ADRA2B gene results in reduced functionality of the α2b-
adrenergic autoreceptor and presumed potentiation of central noradrenergic transmission. 
This variant has been associated with enhanced emotional memory in humans (de Quervain 
et al.  2007). A G to A missense variant of the COMT gene (met 158) results in reduced 
functionality the catechol-O-methyl transferase enzyme responsible for the degradation of 
dopamine in the prefrontal cortex and presumed higher extracellular dopamine levels (Chen 
et al.  2004). This variant has been associated with enhanced episodic memory as well as 
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exaggerated amygdala and prefrontal cortical responses to emotional stimuli relative to the 
val158 allele (de Frias et al.  2004; Smolka et al.  2005). However, no studies have so far 
investigated the effects of interaction between these gene systems on memory formation. 
 
In this study we set out to determine whether the ADRA2B and COMT genotypes would 
interact to modulate emotional and non emotional memories. We predicted that episodic 
memory performance would be better in COMT met158 carriers and this variant would 
produce additive effects in combination with the ADRA2B deletion variant to produce 
greater emotional enhancement of memory.  
 
Experimental Procedures 
Memory testing and genotyping in relation to the ADRA2B deletion and COMT val158met 
polymorphisms were carried out in 97 Caucasian healthy male volunteers aged 18 – 35 years 
(mean = 24.1, SD = 4.8). The study was approved by the King’s College London Research 
Ethics Committee and all participants gave written informed consent. During the encoding 
phase participants viewed 92 pictures from the International Affective Picture System 
(IAPS)(Lang et al.  1998). Half of them were negative-arousing (mean valence = 2.6, SD = 
0.9 and mean arousal = 6.1, SD = 0.6) and half were neutral (mean valence= 5. 1, SD = 0.6 
and mean arousal = 3.3, SD = 0.8). The pictures were presented on a laptop computer for 3 
seconds with a 4 second inter-stimulus interval (ISI), during which a fixation cross was 
present on the screen. The order of presentation was randomized across participants. 
Estimates of verbal IQ were derived from the National Adult Reading Test (NART). Delayed 
memory was tested 1 week later when participants returned for an unexpected recognition 
memory test in which they viewed all of the 92 previously seen pictures and 92 foils matched 
for content, valence and arousal. After each picture, participants made an “old”/“new” 
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judgment and rated the arousal and valence of each picture using a 9-point scale. The hit rate 
(HR) and false alarm rate (FAR) were calculated for each participant and memory accuracy 
was assessed by the calculation of the discrimination index (Pr) based on two-high-threshold 
theory (Snodgrass and Corwin, 1988).  
 
DNA extraction from buccal swabs was carried out by KBiosciences using their internal 
GuSCN-based extraction protocol and genotyping was carried out using their PCR SNP 
genotyping system (KASPar®). 1.5ul DNA (@ ~10ng/ul) per well, dried down before PCR 
onto KBioscience 384-well plates, 4ul PCR volume (using 2x KASPar genotyping system 
reagent) at 94degC for 15min (94degC for 10sec, 57degC for 60s) x36 cycles. Plates were 
read using a BMG PheraStar microtitre plate fluorescence reader. 
Two forward primers and one reverse primer were used as follows for ADRA2B: 
pF1:GAAGGTGACCAAGTTCATGCTCCTCCTCCTCCTCCTCTTCA (detects 'Short' 
allele) and  
pF2:GAAGGTCGGAGTCAACGGATTCCTCCTCCTCCTCCTCTTCC (detects 'Long' 
allele) 
pR:GAAGGAGGGTGTTTGTGGGGCAT and COMT: 
pF1:GAAGGTGACCAAGTTCATGCTGGCATGCACACCTTGTCCTTCAT (detects 'A' 
allele) 
pF2:GAAGGTCGGAGTCAACGGATTGCATGCACACCTTGTCCTTCAC (detects 'G' 
allele) 
pR:CATCACCCAGCGGATGGTGGAT 
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Results 
Of the 97 participants, 9 were homozygous carriers of the ADRA2B deletion, 48 
heterozygotes and 41 did not carry the deletion. Due to the small number of homozygous 
carriers, they were combined with the heterozygotes. 35 participants were homozygous for 
the met158 allele of the COMT gene, 25 were homozygous for the val158 allele and 37 were 
heterozygous. These frequencies did not deviate from Hardy-Weinberg equilibrium. 
Repeated measures analysis of variance revealed that memory accuracy as measured by Pr 
was significantly greater for negative-arousing pictures than neutral pictures [F = 29.0, 
degrees of freedom = 1, error degrees of freedom = 91, p < 0.001]. However there was no 
effect of ADRA2B or COMT genotype on emotional memory as assessed by the absence of 
both 2-way and 3-way arousal x genotype interactions. However, there was a highly 
significant interaction between ADRA2B and COMT genotype [F(2, 91) = 6.7, p = 0.002] 
accompanied by a trend towards a significant main effect of COMT on overall memory 
performance [F(2, 91) = 2.7, p = 0.07] (Fig 1). Mean memory performance measures (hit rate, 
false alarm rate and Pr) for aversive and neutral stimuli by genotype are given in Table 1. 
There were no group differences in age or IQ.  
 
Discussion 
In line with previous studies, our results are indicative of episodic memory impairment in 
carriers of the COMT val 158 allele relative to the met158 allele. However, we demonstrate for 
the first time that this disadvantage is abolished by possession of the ADRA2B deletion 
variant. This is the first demonstration of an effect of ADRA2B genotype on episodic 
memory performance and its interaction with COMT. This suggests that genes that do not 
exert direct effects on cognition might do so indirectly via gene-gene interactions. Our 
hypotheses relating to the effects on emotional enhancement of memory were not confirmed. 
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The enhanced cognitive performance associated with COMT met158 allele carrier status has 
been attributed to enhanced dopaminergic, rather than noradrenergic transmission in the 
prefrontal cortex (Tunbridge et al.  2006). However, prior studies described above have 
indicated that noradrenergic transmission in other brain regions may play a role in 
modulating this effect. Our findings suggest that enhanced noradrenergic transmission as a 
result of reduced function of the α2b-adrenergic autoreceptor may compensate for the 
reduction in dopamine related activity of the prefrontal cortex associated with the higher 
activity COMT met158 allele. However, the neuroanatomical substrate for this effect remains 
unclear. 
 
We also demonstrated a reduction in memory performance in ADRA2B deletion carriers 
relative to non deletion carriers in COMT met158 allele heterozygotes. This may be related to 
the observed inverted-U-shaped relationship between catecholamine levels and pre-frontal 
cortical function (Meyer-Lindenberg et al.  2005). Given that met/met individuals are 
hypothesised to have near-optimal central catecholamine function, increased noradrenergic 
transmission via the ADRA2B deletion may result in a relative impairment in memory 
performance.  
 
One limitation of this study is the relatively small sample size that may have contributed to 
our failure to demonstrate arousal x genotype effects. This failure may also be related to the 
use of recognition memory testing as opposed to recall. Although emotional arousal may lead 
to enhanced recall of information, it may not always lead to increased accuracy on 
recognition memory testing (Windmann and Kutas, 2001). This has been attributed to an 
emotion-induced sense of familiarity, leading to a more liberal response bias, i.e. an increased 
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tendency to classify stimuli as previously seen, irrespective of whether they have been or not 
(Dougal and Rotello, 2007). Under such circumstances, the response bias criterion may 
provide a better marker of emotional modulation of memory. 
 
Recent pharmacogenetic approaches to therapeutic drug development for neuropsychiatric 
disorders have begun to examine the interaction between genetic variation and cognitive 
response. For example, pre-clinical studies in healthy volunteers indicate that the COMT 
inhibitor tolcapone interacts with COMT genotype in producing effects on cognition, such 
that val/val genotypes exhibit improvement and met/met genotypes worsen (Apud et al.  
2006). This is consistent with our findings which may have implications for future 
neuropharmacological attempts to enhance cognition via the noradrenergic system. 
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Table 1: Mean memory performance measures (hit rate, false alarm rate and Pr) for aversive 
and neutral stimuli by genotype. 
 
Performance Measure ADRA2B COMT Stimulus Mean SD 
Hit Rate No deletion val/val Aversive .70 .23 
     Neutral .55 .21 
   val/met Aversive .80 .12 
     Neutral .69 .12 
   met/met Aversive .82 .08 
     Neutral .69 .12 
 Deletion val/val Aversive .81 .10 
     Neutral .69 .14 
   val/met Aversive .80 .11 
     Neutral .63 .14 
   met/met Aversive .76 .13 
     Neutral .62 .14 
False Alarm Rate No deletion val/val Aversive .25 .13 
     Neutral .21 .13 
   val/met Aversive .22 .15 
     Neutral .15 .14 
   met/met Aversive .18 .07 
     Neutral .13 .07 
 Deletion val/val Aversive .21 .13 
     Neutral .14 .08 
   val/met Aversive .19 .10 
     Neutral .11 .07 
   met/met Aversive .19 .08 
     Neutral .15 .10 
Discrimination No deletion val/val Aversive .46 .16 
Index (Pr)     Neutral .35 .20 
   val/met Aversive .58 .19 
     Neutral .53 .16 
   met/met Aversive .64 .11 
     Neutral .56 .15 
 Deletion val/val Aversive .60 .16 
     Neutral .55 .12 
   val/met Aversive .61 .11 
     Neutral .52 .11 
   met/met Aversive .57 .14 
     Neutral .46 .16 
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Figure legends 
 
Figure 1  
Discrimination index (Pr) for all items. There was no difference in memory performance 
between COMT genotypes in those with the ADRA2B deletion. However, in the absence of 
the deletion memory performance of homozygous COMT val158 carriers was significantly 
worse than carriers of the metl158 allele. ** p < 0.01,* p < 0.05. 
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Abstract  
Emotional enhancement of memory is a widely accepted phenomenon that, in addition to its 
adaptive role, may play a role in the evolution of psychiatric disorders. Hence a 
comprehensive understanding of its neurobiological basis is imperative. Whilst the 
pharmacological and neural mechanisms are well known, the contribution of genetic variation 
is not. Research suggests that two qualitatively different processes (recollection and 
familiarity) contribute to recognition memory. In this study, we examined the relative 
contribution of two common genetic polymorphisms, the deletion variant of the ADRA2B 
gene that codes the α2b adrenergic receptor and the val158met polymorphism of the COMT 
gene that codes the catechol-O-methyltransferase enzyme, to emotional enhancement of these 
two memory processes in 97 healthy male volunteers. There was a significant interaction 
between COMT genotype and emotional arousal in relation to recollection, but not 
familiarity, with the former being significantly elevated for emotionally arousing vs. neutral 
pictures in carriers of the val158 allele compared to met158 carriers. There were no main 
effects or interactions in relation to ADRA2B genotype. 
 
Key words: 
Genetics; emotional memory; episodic memory; COMT; ADRA2B, catecholamines; 
noradrenaline 
Naudts KH et al., 2012, J. Psychopharmacology, 26(6):819-829 
37 
 
 
1. Introduction 
It is well established that memory is enhanced for emotional compared to neutral events and 
experiences (Brown and Kulik, 1977). Whilst this phenomenon, termed ‘emotional memory’, 
has long been held to confer an evolutionary advantage related to the enhanced retention of 
information relevant to survival, there is increasing evidence that it may also contribute to 
psychopathological processes. For example, the intrusive reliving of traumatic memories 
associated with post-traumatic stress disorder (PTSD) is considered to be a maladaptive 
consequence of emotional memory processes (Elzinga and Bremner, 2002;Labar and Cabeza, 
2006). Such processes are also hypothesised to contribute to abnormal belief formation in 
psychotic disorders (Fotopoulou, 2010;Gibbs and David, 2003). Thus, understanding the 
mechanisms of emotional memory formation and maintenance has become an increasingly 
important domain of cognitive neuroscience research. 
 
Emotional memory has been investigated experimentally using a variety of stimuli including 
words (Kleinsmith and Kaplan, 1963), pictures (Bradley et al., 1992) and stories (Cahill and 
McGaugh, 1995), although the extent to which these laboratory paradigms accurately reflect 
real-life emotional memories has been questioned (Todd et al., 2011). Nevertheless, a wealth 
of research using these paradigms has elucidated many of the neurobiological mechanisms 
underlying emotional enhancement of memory. For example, initial lesion studies in humans 
demonstrated that the amygdala is a key neural substrate for emotional enhancement of 
memory (Adolphs et al., 1997;Cahill et al., 1995) and this has been confirmed in multiple 
subsequent functional neuroimaging studies (Cahill et al., 1996;Canli et al., 1999;Canli et al., 
2000;Hamann et al., 1999). Pharmacological challenge studies with beta blockers and 
dopamine antagonists in healthy human volunteers have demonstrated the crucial role of the 
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catecholamine neurotransmitters noradrenaline and dopamine (Cahill et al., 1994;van 
Stegeren et al., 1998;van Stegeren et al., 2002;Gibbs et al., 2007) and multiple functional 
magnetic resonance imaging (fMRI) studies have confirmed the role of noradrenergic 
transmission in amygdala mediated consolidation of emotional memories (van Stegeren et al., 
2005;van Stegeren, 2008). Although similar pharmacological fMRI studies have not yet been 
conducted in relation to the effects of dopamine on emotional memory, there is evidence that 
dopamine is involved in modulating the human amygdala response (Takahashi et al., 
2010;Takahashi et al., 2005;Tessitore et al., 2002) and its contribution to emotional memory 
has been established in a plethora of animal studies (Greba et al., 2001;Guarraci et al., 
1999;Guarraci et al., 2000;LaLumiere et al., 2004).  
 
However, the contribution of genetic variation to human emotional memory has only recently 
begun to be investigated. As yet, little is known about the factors underlying individual 
differences in emotional memory that might contribute to individual vulnerability or 
resilience to psychological disorders such as PTSD (Todd and Anderson, 2009). Consistent 
with existing literature, it has been hypothesised that genes contributing to noradrenergic and 
dopaminergic neurotransmission (ADRA2B and COMT) are likely to contribute to individual 
differences in emotional enhancement of memory (Todd et al., 2011). For instance, a 
polymorphic deletion in the ADRA2B gene has been linked to emotional memory. This 
deletion results in reduced agonist–promoted desensitisation of the α2b adrenergic 
autoreceptor in vitro and is therefore presumed to contribute to potentiation of noradrenergic 
transmission (Small et al., 2001). Although this has not been directly demonstrated in vivo, 
indirect behavioural and neuroimaging data support this assumption. Two studies have 
demonstrated that recall of emotionally arousing, compared to neutral images is enhanced in 
ADRA2B deletion carriers relative to non carriers (de Quervain et al., 2007) and this is 
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associated with increased amygdala activation during encoding (Rasch et al., 2009). The 
finding that the deletion variant was also associated with increased PTSD symptoms 
highlights the potential clinical relevance of genetically influenced emotional memory. 
However, two factors limit the conclusions that can be drawn about the role of ADRA2B in 
long-term emotional enhancement of memory from these two seminal studies. First, memory 
was tested after a very short (10 minute) retention interval and second, the observed 
genotype-related differences in amygdala activation during encoding were not associated 
with subsequent memory for the emotional stimuli. Thus, the contribution of ADRA2B to 
longer-term consolidation processes remains unclear. On the other hand, COMT has not been 
directly linked to emotional memory although the relationship between the COMT 
polymorphism and dopamine levels has been demonstrated in vivo (Gogos et al., 1998). A 
common polymorphism (val158met) in this gene, the substitution of methionine (met) for 
valine (val) results in a functional reduction in the activity of the enzyme, catechol-O-
methyltransferase (COMT), responsible for the degradation of dopamine in the prefrontal 
cortex. The met allele is associated with 40% less COMT activity (Chen et al., 2004), 
resulting in higher levels of dopamine in the prefrontal cortex. However the behavioural 
effects of this polymorphism are complicated by increasing evidence of pleiotropy3 (Mier et 
al., 2009). For example, initial studies suggested that the met allele is associated with 
enhanced prefrontal cognitive function, particularly executive function (Egan et al., 
2001;Bertolino et al., 2006), but also episodic memory  (de Frias et al., 2004). However, 
other evidence suggests that the COMT val158met polymorphism may also play a role in 
individual responses to emotional stimuli. A number of more recent studies suggest that the 
met allele is also associated with an increased neural response to aversive, relative to neutral 
and positive stimuli, specifically involving the amygdala and prefrontal cortex (Herrmann et 
                                                 
3
 Pleiotropy refers to the process by which a single gene exerts multiple behavioural effects. 
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al., 2009;Drabant et al., 2006;Smolka et al., 2007;Smolka et al., 2005). Thus, although there 
is no behavioural or neuroimaging evidence directly linking the COMT val158met 
polymorphism to emotional memory, its role in the reactivity of brain regions crucial to the 
emotional enhancement of memory is indicative. 
 
It has therefore been suggested that both ADRA2B and COMT are likely to play a role in 
individual variation in emotional memory, with ADRA2B contributing to emotional 
enhancement of consolidation processes by influencing the amygdala and hippocampus, 
whilst COMT’s role may be more likely to relate to prefrontal regulation of amygdala 
responses to emotional (aversive) stimuli (Todd et al., 2011).  This is consistent with the 
‘modulation hypothesis’ suggesting that emotional enhancement of memory occurs via 
interaction between in prefrontal-amygdala-hippocampal networks. This is supported by 
existing fMRI data demonstrating that subsequent memory effects for emotionally arousing 
stimuli can be predicted by correlated activation between these regions during encoding 
(Dolcos et al., 2004;Kilpatrick and Cahill, 2003;Richardson et al., 2004). Few studies have as 
yet attempted to investigate potential interactive (epistatic) effects of these genes on 
emotional memory. We recently began to address this gap by investigating epistasis between 
the ADRA2B deletion and COMT val158met polymorphisms on emotional memory in 
healthy human volunteers. We found a significant interaction between the two 
polymorphisms in relation to overall episodic memory performance. Specifically, ADRA2B 
deletion carriers who were homozygous for the COMT val allele showed better memory for 
both neutral and aversive stimuli than non carriers, suggesting that possession of the deletion 
variant may moderate the cognitive impairments associated with the COMT val allele (Gibbs 
et al., 2010b). We hypothesised that this is related to the putative inverted “U” that has been 
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proposed to model the effects of catecholamine levels on prefrontal cognitive function 
(Meyer-Lindenberg et al., 2005)(see Figure 1).  
 
[Figure 1 about here please] 
 
Ostensibly, by increasing prefrontal noradrenaline levels, the ADRA2B deletion variant shifts 
high activity COMT val/val individuals to more optimal catecholamine levels and 
consequently, improved cognitive performance. However, unlike de Quervain et al, we did 
not find an effect of either gene on emotional enhancement of memory per se (de Quervain et 
al., 2007). This may have been due to reduced power in our smaller sample which would be 
consistent the absence of behavioural differences in their fMRI study, presumed to be due to 
the smaller sample size (Rasch et al., 2009). However, the discrepancy may have been due to 
methodological differences. For example, in order to explore the contribution of genetic 
variation to longer-term consolidation processes, we examined memory after a delay of one 
week, rather than the ten minute interval used by de Quervain et al. We also used an “old-
new” recognition memory test, as opposed to free recall, in order to examine other processes 
that may be influenced by emotional arousal, such as memory confidence. In such one-
interval designs, measures of accuracy or discrimination (d') may be derived from single-
process memory models based on signal detection theory (SDT) (Green and Swets, 1966). In 
these models d' is considered to relate to a single process of memory strength, or familiarity, 
from which confidence judgements arise directly (Egan, 1958). However, dual-process signal 
detection (DPSD) models have increasingly been used to account for data indicating that two 
distinct processes may contribute to recognition memory: recollection and familiarity 
(Yonelinas, 2002). The latter is considered to be a quantitative, memory-strength based 
process, associated with a “sense of having previously seen”. By contrast, recollection is 
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presumed to be a qualitative threshold process, associated with high levels of contextual 
detail and high confidence judgements, and is considered most closely related to recall 
performance (Mandler, 1980). It is possible that differential effects of genotypes on 
emotional enhancement of these two different memory processes may account for the 
difference between our findings and those of de Quervain et al 2007. Therefore, in the present 
study, we used a DPSD approach to investigate the relative contribution of variation in the 
ADRA2B and COMT genotypes (including possible interactions) to the recollection and 
familiarity components of emotional memory.  
 
2. Materials and methods 
 
2.1. Participants 
One hundred and seven healthy white British male volunteers, aged 18 to 40 years (mean age 
= 24.1, SD = 4.8) were recruited through an advertisement and received financial 
compensation for their participation. Potential participants were screened for psychiatric or 
neurological disorder by means of a checklist questionnaire.  Exclusion criteria were (i) any 
current or past history of psychiatric illness, (ii) any significant history of substance misuse, 
including nicotine, and (iii) taking regular medication. Estimates of verbal IQ were derived 
from the National Adult Reading Test (NART) (Nelson, 1982). The study was approved by 
the King’s College London Research Ethics Committee and all participants gave written 
informed consent. 
 
2.2. Genetic Testing 
This was carried out as previously reported (Gibbs et al., 2010b). Specifically, DNA 
extraction from buccal swabs was carried out by KBioscience using their internal GuSCN-
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based extraction protocol and genotyping was carried out using their PCR SNP genotyping 
system (KASPar®). 1.5ul DNA (@ ~10ng/ul) per well, dried down before PCR onto 
KBioscience 384-well plates, 4ul PCR volume (using 2x KASPar genotyping system reagent) 
at 94degC for 15min (94degC for 10sec, 57degC for 60s) x36 cycles. Plates were read using a 
BMG PheraStar microtitre plate fluorescence reader. Two forward primers and one reverse 
primer were used as follows for ADRA2B:  
pF1:GAAGGTGACCAAGTTCATGCTCCTCCTCCTCCTCCTCTTCA  (detects'Short' 
allele) and  
pF2:GAAGGTCGGAGTCAACGGATTCCTCCTCCTCCTCCTCTTCC (detects 'Long' 
allele) 
pR:GAAGGAGGGTGTTTGTGGGGCAT and COMT: 
pF1:GAAGGTGACCAAGTTCATGCTGGCATGCACACCTTGTCCTTCAT (detects 'A' 
allele) 
pF2:GAAGGTCGGAGTCAACGGATTGCATGCACACCTTGTCCTTCAC (detects 'G' 
allele) 
pR:CATCACCCAGCGGATGGTGGAT 
 
2.3. Emotional Memory Task 
We used an emotional memory task similar to that previously used by ourselves and others 
(de Quervain et al., 2007;Gibbs et al., 2007;Gibbs et al., 2010b;Rasch et al., 2009).  During 
the encoding phase participants viewed 92 pictures from the International Affective Picture 
System (IAPS) stimulus set (Lang et al., 1998). Half were aversive-arousing (mean valence = 
2.6, SD = 0.9 and mean arousal = 6.1, SD = 0.6) and half were neutral (mean valence= 5. 1, 
SD = 0.6 and mean arousal = 3.3, SD = 0.8). Evidence suggests that the effects of emotional 
arousal on memory are larger and more consistently observed for aversive compared to 
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positive emotional stimuli (Kensinger and Corkin, 2004;de Quervain et al., 2007;Rasch et al., 
2009). Additionally, the evidence to date suggests that COMT is associated with altered 
processing of aversive, but not positive stimuli.  Hence we chose to use only aversive 
emotional stimuli given that we were interested in the effects of arousal, rather than valence 
per se. The pictures were presented on a laptop computer for 3 seconds with a 4 second inter-
stimulus interval (ISI), during which a fixation cross was present on the screen. The order of 
presentation was randomised across participants. Participants were instructed to observe the 
picture while it was being presented and make a binary judgement as to whether they 
considered the image emotionally arousing or non arousing by pressing one of two laptop 
keys. Delayed memory was tested one week later when participants returned for an 
unexpected recognition memory test in which they viewed all of the 92 previously seen 
pictures and 92 foils matched for content, valence and arousal. Participants were required to 
judge whether each picture was “old” (previously seen) or “new” (not previously seen) and 
then rate their confidence in this judgement using a scale ranging from “uncertain” to “very 
certain”. In order to reduce the likelihood of participants making only high-confidence or 
low-confidence judgements, they were advised to make use of the entire scale. Participants 
were also asked to rate each picture for arousal and valence on scales ranging from “calm” to 
“aroused” and “unpleasant” to “pleasant”, respectively, in line with previous approaches 
(Lang et al., 1988)  
 
2.4. Statistical Analysis 
Hit rates (proportion of previously seen items correctly identified as ‘old’) and false alarm 
rates (proportion of foils incorrectly identified as ‘old’) for each stimulus category were 
calculated for each participant. Estimates of recollection (R) and familiarity (d') for each 
participant were derived from receiver operating characteristic (ROC) curves generated by 
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plotting performance (hit rate vs. false alarm rate) as a function of response confidence. This 
was carried out using a Microsoft Excel solver that used model dual-process equations to 
reduce the sum of squared errors between the predicted and observed data (Yonelinas et al., 
1998). The number of items in each confidence category was examined to ensure that 
participants had followed the instructions to utilise the entire confidence scale. This was 
necessary as evidence suggests that failure to use the entire scale leads to ROC points that are 
closely clustered together, making it difficult to accurately assess the function.  
 
3. Results  
 
3.1. Genotypes 
Of the 107 participants, ADRA2B genotypes were missing for 2 participants, 11 were 
homozygous carriers of the ADRA2B deletion, 48 were heterozygotes and 46 were non 
carriers. These frequencies did not deviate from Hardy-Weinberg equilibrium (Χ2=0.09, 
p=0.77). Due to the small number of homozygous carriers, they were combined with the 
heterozygotes, giving two genotype groups of deletion carriers (del) and non-carriers (no del) 
as previously done by de Quervain et al 2007. COMT genotype was missing for 1 participant. 
Thirty-six participants were homozygous for the met158 allele, 27 were homozygous for the 
val158 allele and 43 were heterozygous, consistent with Hardy-Weinberg equilibrium 
(Χ2=3.54, p=0.06). Seven participants failed to attend for recognition memory testing and 
were excluded from further analysis. Genotype frequencies of participants included in the 
analysis are given in Table 1. Demographic characteristics (age and IQ) are given in Table 2. 
IQ data were missing for two participants. Differences in demographic variables between 
genotype groups were assessed in a multivariate Analysis of Variance (ANOVA) with age 
and IQ as dependent variables and ADRA2B (del, no del) and COMT (val/val, val/met, 
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met/met) genotypes as between-subjects factors. There were no significant main effects of 
genotype and no interactions. 
 
[Tables 1 and 2 about here] 
 
3.2. Arousal and valence ratings 
There were no differences between genetic variants in arousing vs. non arousing judgements 
made at encoding for COMT (Χ2=1.7, p =0.42) or ADRA2B (Χ2=1.9, p=0.16). The ratings 
made at recognition memory testing were significantly correlated with the standardised 
ratings for valence (r=0.72, p<0.0001) and arousal (r=0.63, p<0.0001). These ratings were 
entered into separate repeated measures ANOVA with emotional category (aversive, neutral) 
and stimulus category (encoding, foil) as the within-subject factors and ADRA2B (del, no 
del) and COMT (val/val, val/met, met/met) genotypes as between-subjects factors. There was 
a main effect of emotional category on both arousal [F(1, 91)=424.96, p < 0.001] and valence 
[F(1, 91)=897.6, p < 0.001] with emotional pictures being rated as significantly more 
arousing [mean(SD) = 6.53(1.08) vs. 4.03(1.04)] and more unpleasant [mean(SD) = 
3.01(0.94) vs. 5.53(0.64)] than neutral. There were no main effects of genotype or stimulus 
category and no interactions.   
 
 
3.2. Emotional Memory  
R and d' were entered into separate repeated measures Analysis of Variance (ANOVA) with 
emotional category (aversive, neutral) as the within-subject factor and ADRA2B (del, no del) 
and COMT (val/val, val/met, met/met) genotypes as between-subjects factors. This revealed a 
significant emotion x COMT interaction [F(2, 90) = 3.4, p = 0.04] on recollection that 
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accounted for 7% of the variance in the model, see Figure 2. There were no other main 
effects or interactions. Post hoc independent t-tests indicated that recollection estimates were 
significantly greater in COMT val/val [t(57)=2.52, p=0.01] and val/met [t(70)=2.60, p=0.01]  
individuals compared to met/met for aversive, but not neutral stimuli. ANOVA did not reveal 
any main effects or interactions in relation to familiarity. Mean hit/false alarm rates, 
confidence ratings, recollection/familiarity estimates are given in Tables 3, 4, and 5 
respectively. The average ROC curves for the aversive and neutral conditions for the COMT 
val/val and met/met genotypes are presented in Figure 3a-d. 
 
[Tables 3, 4 and 5 and Figure 3 about here please] 
 
We have previously reported analyses of the standard SDT parameters sensitivity (d') and 
response bias (C), in which we found no effect of COMT on emotional enhancement of 
memory (Gibbs et al., 2010b). However in the present analysis, we additionally examined d' 
based on hit rate and false alarm rate parameters derived only from responses in the highest 
confidence category. This produced a significant interaction between COMT and ADRA2B 
on overall memory performance, as previously reported, but no other significant main effects 
or interactions. However, in the model including only high confidence responses, the 
interaction between COMT genotype and arousal explained a greater proportion of the 
variance (3%) than the model including all responses (1%).  
 
4. Discussion 
The aim of this study was to explore the contribution of genetic variation to the recollection 
and familiarity components of emotional enhancement of memory and to the best of our 
knowledge, this is the first study to do so. Given that previous studies have indicated that the 
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catecholamine neurotransmitters dopamine and noradrenaline play a key role in emotional 
processing, we examined the influence of two functional polymorphisms involved in 
catecholamine signalling (COMT val158met and the ADRA2B deletion polymorphism) on a 
dual process signal detection (DPSD) model of emotional memory. We found a significant 
interaction effect between COMT val158met genotype and emotional arousal on the 
recollection component of recognition memory. Specifically, long-term recollection for 
emotionally arousing, but not neutral stimuli was impaired in met/met individuals, compared 
to val/val and val/met individuals. Although this interaction explained only a small 
proportion of the variance in the model, the observed increases in effect size when using 
DPSD measures vs. standard signal detection theory (SDT) measures based on high-
confidence responses vs. standard SDT measures based on all responses further supports the 
validity of the DPSD approach in this case. No prior studies have directly investigated the 
potential link between the COMT val158met polymorphism and emotional memory. The 
present findings, along with our previous report constitute the first published attempts to do 
so. Our present data suggest COMT moderation of high confidence recollective emotional 
memory processes, but not low confidence familiarity-based ones. This may be attributable to 
one of two possibilities: (i) a specific effect of COMT genotype on recollection, but not 
familiarity or (ii) greater power to detect effects on recollection given that emotional arousal 
is known to boost recollection to a greater degree than familiarity (Ochsner, 2000;Sharot et 
al., 2007;Gibbs et al., 2010a). The increasing effect sizes when moving from analysis of 
decisions made with any level of confidence levels to high confidence decisions to 
recollection, supports the latter scenario. This suggests that future studies aiming to 
investigate effects of COMT genotype on emotional modulation of recognition memory may 
maximise detection of statistically significant results by limiting analyses to responses made 
with the highest degree of confidence, or adopting a DPSD approach.   
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Prior to this, no studies had specifically examined the role of COMT in declarative emotional 
memory.  In the absence of an existing body of behavioural emotional memory literature, it is 
difficult to interpret our findings in the context of specific differential effects of the val vs. 
met alleles. Previous studies investigating links between COMT and emotional processing 
have focussed on neural (as opposed to behavioural) effects and found that carriers of the met 
allele showed greater prefrontal cortical and amygdala activation in response to aversive 
scenes compared to carriers of the val allele (Domschke et al., 2008;Drabant et al., 
2006;Smolka et al., 2005;Yacubian et al., 2007). It has therefore been suggested that the 
effect of COMT on emotional memory might relate to prefrontal regulation of amygdala 
reactivity to aversive events, in turn influencing consolidation of such events (Todd et al., 
2011). This would be in keeping with the established role of the amygdala in modulating 
emotional memory (Cahill et al., 1996;Canli et al., 1999;Canli et al., 2000). However these 
studies clearly document positive correlations between amygdala activation and emotional 
enhancement of memory, suggesting that the increased activation amygdala activation 
observed in met carriers would predict enhanced, rather than impaired recollection for 
aversive stimuli as we observed. However, the relationship between the magnitude of brain 
activation as detected by functional neuroimaging and task performance remains complex 
and poorly understood. For example, some brain regions such as the prefrontal cortex appear 
to demonstrate a distinctive ‘inverted U’ or ‘capacity-constrained’ pattern of brain activation 
in relation to performance, such that the two are positively correlated up to the point that a 
capacity is reached, after which performance typically declines, and is uncoupled from brain 
activation  (Callicott et al., 1999). Whilst this principle has not been specifically investigated 
in relation to the amygdala and other limbic structures involved in emotional memory, a 
similar pattern may also be applicable. For example, above a certain threshold, amygdala 
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activation may cease to enhance memory performance and begin to result in impairment. This 
would explain our present findings and would be consistent with other work supporting an 
inverted-U shaped relationship between corticosteroids and cognition, including episodic 
memory performance (Roozendaal, 2000;Lupien and McEwen, 1997;Wolkowitz et al., 1990). 
However, functional neuroimaging studies examining the relationship between COMT 
genotypes and brain activation associated with successful encoding of emotional stimuli will 
be necessary to clarify the neural basis of these genotype effects on emotional memory. 
 
Three prior studies have investigated ADRA2B influences on emotional memory. In a large 
single-gene study, de Quervain and colleagues examined 435 Swiss participants and found 
that carriers of the deletion variant showed significantly greater recall memory for emotional 
(positive and negative) vs. neutral pictures compared to non carriers (de Quervain et al., 
2007). In a further study to examine the relationship between genotype-dependent differences 
in brain activation and emotional memory, they collected fMRI from 57 participants using the 
same emotional memory task (Rasch et al., 2009). Deletion carriers demonstrated 
significantly increased amygdala activation in response to emotionally arousing pictures 
compared to non carriers, although no behavioural differences in emotional memory were 
observed. This was considered due to low statistical power (32%) to detect the effect size of 
0.4 in this much smaller sample. In an independent study examining both COMT and 
ADRA2B genotype influences on emotional memory in 97 British participants using aversive 
emotional pictures, we did not find any ADRA2B-related differences in emotional memory 
for aversive compared to neutral pictures based on standard SDT parameters (Gibbs et al., 
2010b). In the present analysis of these data using a DPSD approach, we also did not find any 
main effect of the ADRA2B genotype on emotional enhancement of recollection or 
familiarity processes. In both cases this may be due to insufficient statistical power (60%) 
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based on the effect size reported in the Swiss study. However, other methodological 
differences may also be relevant. Firstly, we used a 1 week interval between encoding and 
memory testing as opposed to their short 10 minute retention interval. It is possible that the 
genotype-dependent differences observed by de Quervain and colleagues relate to encoding 
processes, such as attention and perception, influencing short-term memory, as opposed to 
the consolidation processes contributing to long-term memory. This would be consistent with 
their fMRI findings where ADRA2B genotype-dependent differences in amygdala activation 
were observed during encoding but did not influence subsequent memory. However, given 
that memory was tested at a single time point in both studies, it remains unclear whether the 
effects are due to encoding or consolidation processes, or both. Further studies will be 
necessary to clarify the effects of ADRA2B on the affective modulation of 
attention/perception during encoding and the effects of post-encoding arousal (Todd et al., 
2011). Although no genotype effects on emotional memory were found in our prior study, we 
did observe a significant interaction between COMT and ADRA2B on recognition memory 
for both aversive and neutral pictures, such that possession of the ADRA2B deletion 
appeared to ameliorate the impairment associated with the COMT val allele (Gibbs et al., 
2010b). Yet no such interaction was observed in relation to recollection and familiarity in the 
present analysis. This may be because the epistatic effects of the two genes on overall 
recognition memory may influence both recollection and familiarity and examining these 
processes separately may have resulted in a loss of power. Further studies are warranted 
using larger samples. 
 
In addition to issues that may have arisen due to low statistical power, there are a number of 
limitations to our study. The COMT genotypes included in the final analysis deviated from 
HWE, raising the possibility of genotyping error or a selection bias limiting the 
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generalisability of our findings. However, we consider this unlikely given that both genotypes 
were in HWE in the full sample of recruited individuals, although we acknowledge that the 
X2 analysis for COMT was suggestive of trend-level statistical significance. Additionally, we 
used an all male group due in order to avoid confounding the established gender differences 
in emotional memory and its neural correlates (Cahill, 2006) as well as sexually dimorphic 
effects of COMT (Chen et al., 2004;Harrison and Tunbridge, 2007;Gogos et al., 1998).  
Therefore, the extent to which the present findings are applicable to women remains unclear 
and will warrant further investigation in larger mixed-gender samples to allow adequate 
control for possible gender effects. Furthermore, we used only aversive emotionally arousing 
pictures. This is justified by the accumulating evidence that COMT preferentially influences 
processing of aversive as opposed to positive emotional stimuli (Herrmann et al., 
2009;Montag et al., 2008;Smolka et al., 2007) and the fact that emotional enhancement of 
memory is arousal-dependent, rather than valence-dependent (Kensinger and Corkin, 2004). 
Nevertheless, the inclusion of only aversive emotional stimuli means that implications of our 
findings for positive emotional experiences are unclear. Finally, we examined only two genes 
amongst a number of variants that may contribute to emotional memory and its components 
(Todd et al., 2011). It is increasingly understood that epistatic effects are likely to be at least 
as important in modulating behavioural phenotypes, if not more so, than single-gene effects 
(Elvevåg and Weinberger, 2009). In fact, it has been suggested that one of the reasons that 
studies of single polymorphisms replicate poorly across independent samples is because 
epistasis is more important (Moore and Williams, 2002). In spite of this, gene-gene 
interactions have rarely been explored in behavioural genetics studies. This is because the 
phenomenon of biological epistasis is poorly understood, its analysis is more complex and as 
the number of genes involved increases, exponentially larger sample sizes are needed to 
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estimate interaction effects (Moore, 2008). Indeed, the small n for each genotype 
combination in our present study may have limited power to detect such an effect. 
 
In summary, the present study provides preliminary behavioural evidence concerning the 
effect of the COMT val158met polymorphism on the recollection component of emotional 
memory. As such, it contributes to an important emerging area of cognitive neuroscience 
research: the role of genetic variation in emotional enhancement of memory. It also begins to 
disentangle the effects in relation to two different forms of episodic memory: recollection and 
familiarity. However, it is acknowledged that the findings reported are preliminary and future 
studies are needed to independently replicate and extend this work.  
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Tables 
 
Table 1 – Genotype Frequencies 
 
Genotype  COMT 2  
ADRA2B 1 val/val val/met met/met 
Total 
del/del 1 3 4 8 del 
del/no del 16 17 15 48 
no del no del/no del 8 17 16 41 
 Total 25 37 35 97 
1 X2 = 1.38, p = 0.24 2 X2 = 5.08, p = 0.02 
 
Naudts KH et al., 2012, J. Psychopharmacology, 26(6):819-829 
63 
 
 
 
Table 2 – Socio-demographic characteristics for COMT and ADRA2B genotypes 
 
 COMT ADRA2B 
 val/val val/met met/met F df p del no del F df p 
Age  
[yrs, mean (SD)] 
24.7 
(5.0) 
24.1 
(5.0) 
23.8 
(4.6) 
0.89 2, 90 0.12 24.8 
(5.1) 
23.2 
(4.3) 
3.04 1, 90 0.08 
IQ [mean (SD)] 106.4 
(7.5) 
105.0 
(5.6) 
106.2 
(5.4) 
0.50 2, 90 0.63 106.7 
(5.7) 
104.7 
(6.4) 
3.43 1, 90 0.07 
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Table 3 – Mean (SD) hit rate and false alarm rate for aversive and neutral stimuli for COMT 
and ADRA2B genotypes  
 
  
 
 
 
 
Hit Rate 
 
False Alarm Rate 
 
COMT 
 
ADRA2B 
 
N 
 
Aversive  
 
Neutral  
 
Aversive  
 
Neutral 
 
val/val 
 
no del 
 
8 
 
0.70(0.23) 
 
0.55(0.21) 
 
0.25(0.13) 
 
0.21(0.13) 
  
 
 
del 
 
17 
 
0.81(0.10) 
 
0.69(0.14) 
 
0.21(0.13) 
 
0.14(0.08) 
 
 Total 
 
 
 
25 
 
0.77(0.16) 
 
0.65(0.17) 
 
0.22(0.13) 
 
0.16(0.10) 
 
val/met  
 
no del 
 
17 
 
0.80(0.12) 
 
0.69(0.12) 
 
0.22(0.15) 
 
0.15(0.14) 
  
  
 
del 
 
20 
 
0.80(0.11) 
 
0.63(0.14) 
 
0.19(0.10) 
 
0.11(0.07) 
  
 Total 
 
 
 
37 
 
0.80(0.11) 
 
0.66(0.13) 
 
0.20(0.13) 
 
0.13(0.11) 
 
met/met  
 
no del 
 
16 
 
0.82(0.02) 
 
0.69(0.12) 
 
0.18(0.07) 
 
0.13(0.07) 
  
  
 
del 
 
19 
 
0.76(0.13) 
 
0.62(0.14) 
 
0.19(0.08) 
 
0.15(0.10) 
  
 Total 
 
 
 
35 
 
0.79(0.11) 
 
0.65(0.14) 
 
0.18(0.08) 
 
0.14(0.08) 
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Table 4 – Mean (SD) confidence ratings for hits and false alarms for aversive and neutral 
stimuli for COMT and ADRA2B genotypes  
 
  
 
 
 
 
Hits 
 
False Alarms 
 
COMT 
 
ADRA2B 
 
N 
 
Aversive  
 
Neutral  
 
Aversive  
 
Neutral 
 
val/val 
 
no del 
 
8 
 
7.33(1.10) 
 
6.93(1.22) 
 
6.25(1.48) 
 
5.40(1.80) 
  
 
 
del 
 
17 
 
7.76(0.72) 
 
6.28(1.56) 
 
6.28(1.56) 
 
4.86(1.33) 
 
 Total 
 
 
 
25 
 
7.62(0.86) 
 
7.13(0.92) 
 
6.27(1.40) 
 
5.03(1.48) 
 
val/met  
 
no del 
 
17 
 
7.72(0.53) 
 
7.28(0.82) 
 
6.01(1.43) 
 
5.18(1.35) 
  
  
 
del 
 
20 
 
7.52(0.61) 
 
7.20(0.82) 
 
5.73(1.30) 
 
5.23(1.38) 
  
 Total 
 
 
 
37 
 
7.61(0.58) 
 
7.23(0.81) 
 
5.86(1.53) 
 
5.21(1.35) 
 
met/met  
 
no del 
 
16 
 
7.87(0.66) 
 
7.49(0.64) 
 
6.43(0.90) 
 
5.59(1.21) 
  
  
 
del 
 
19 
 
7.41(0.87) 
 
6.73(1.19) 
 
5.75(1.40) 
 
4.31(1.66) 
  
 Total 
 
 
 
35 
 
7.62(0.80) 
 
7.08(1.04) 
 
6.06(1.23) 
 
4.90(1.59) 
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Table 5 – Mean (SD) recollection and familiarity estimates for aversive and neutral stimuli 
for COMT and ADRA2B genotypes  
 
  
 
 
 
 
Recollection 
 
Familiarity 
 
COMT 
 
ADRA2B 
 
N 
 
Aversive  
 
Neutral  
 
Aversive  
 
Neutral 
 
val/val 
 
no del 
 
7 
 
0.29(0.32) 
 
0.15(0.14) 
 
1.33(0.96) 
 
0.76(0.46) 
  
 
 
del 
 
17 
 
0.41(0.28) 
 
0.35(0.25) 
 
1.31(0.71) 
 
1.08(0.53) 
 
 Total 
 
 
 
24 
 
0.38(0.29) 
 
0.29(0.24) 
 
1.32(0.77) 
 
0.99(0.52) 
 
val/met  
 
no del 
 
17 
 
0.35(0.30) 
 
0.30(0.20) 
 
1.17(0.81) 
 
1.10(0.53) 
  
  
 
del 
 
20 
 
0.37(0.25) 
 
0.26(0.18) 
 
1.30(0.68) 
 
1.30(0.52) 
  
 Total 
 
 
 
37 
 
0.36(0.27) 
 
0.28(0.19) 
 
1.24(0.74) 
 
1.21(0.53) 
 
met/met  
 
no del 
 
16 
 
0.22(0.30) 
 
0.25(0.19) 
 
1.59(0.55) 
 
1.33(0.59) 
  
  
 
del 
 
19 
 
0.18(0.23) 
 
0.27(0.16) 
 
1.33(0.70) 
 
1.07(0.41) 
  
 Total 
 
 
 
35 
 
0.20(0.26) 
 
0.26(0.17) 
 
1.45(0.64) 
 
1.19(0.51) 
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Figures 
Figure 1 
Title: Inverted “U” shaped model of episodic memory performance against catecholamine 
levels as influenced by genotype.  
 
Description: A putative inverted “U” models the effects of COMT and ADRA2B genotypes 
on episodic memory performance and catecholamine levels in the prefrontal cortex (PFC). By 
presumably boosting noradrenergic catecholamine transmission, the deletion variant of 
ADRA2B shifts COMT val/val individuals - who normally have greater COMT activity, less 
dopaminergic catecholamine transmission, and relatively poorer episodic memory - to the 
right, and more optimal performance. The ADRA2B deletion variant also shifts met/met 
individuals, who are presumed to have optimal prefrontal function, to the right, but to less 
efficient performance. 
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Figure 2 
Title: Recollection estimates in COMT genotypes for aversive and neutral stimuli  
 
Description: There was a significant interaction between COMT genotype and stimulus 
valence on recollection. Recollection estimates were significantly lower in COMT met/met 
genotypes compared to val/val and val/met for aversive, but not neutral stimuli. 
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Figure 3 
Title: ROC curves for COMT val/val and met/met genotypes for aversive and neutral 
conditions plotted in probability space 
 
Description: The x-axis represents the proportion of new pictures incorrectly identified as 
“old”. The y-axis represents the proportion of old pictures correctly identified. The diagonal 
represents chance discrimination. Functions a to c are curvilinear and asymmetrical along the 
diagonal, suggesting contributions of both recollection and familiarity to the recognition 
memory process (Yonelinas et al, 1998). Function b is skewed relative to a, suggesting a 
greater contribution of recollection for the aversive pictures, compared to neutral pictures in 
the val/val genotypes. Function d appears symmetrical along the diagonal, rather than skewed 
relative to c, suggesting that recollection made a limited contribution to the discrimination of 
aversive pictures, compared to neutral pictures in the met/met genotypes.  
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Abstract 
Individual differences in emotional processing are likely to contribute to vulnerability and 
resilience to emotional disorders such as depression and anxiety. Genetic variation is known 
to contribute to these differences but they remain incompletely understood. The serotonin 
transporter (5-HTTLPR) and alpha 2B adrenergic autoreceptor (ADRA2B) insertion/deletion 
polymorphisms impact on two separate but interacting monaminergic signalling mechanisms 
that have been implicated in both emotional processing and emotional disorders. Recent 
studies suggest that the 5-HTTLPR s allele is associated with a negative attentional bias and 
an increased risk of emotional disorders. However such complex behavioural traits are likely 
to exhibit polygenicity, including epistasis. This study examined the contribution of the 5-
HTTLPR and ADRA2B insertion/deletion polymorphisms to attentional biases for aversive 
information in 94 healthy male volunteers and found evidence of a significant epistatic effect 
(p<0.001). Specifically, in the presence of the 5-HTTLPR s allele, the attentional bias for 
aversive information was attenuated by possession of the ADRA2B deletion variant whereas 
in the absence of the s allele, the bias was enhanced. These data identify a cognitive 
mechanism linking genotype-dependent serotonergic and noradrenergic signalling that is 
likely to have implications for the development of cognitive markers for depression/anxiety 
as well as therapeutic drug effects and personalised approaches to treatment. 
 
Keywords: 5-HTTLPR; ADRA2B; emotional processing 
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Introduction 
Enhanced processing of emotionally salient relative to neutral information is normally 
considered to be an adaptive process enabling threat detection and increasing the probability 
of survival (Vuilleumier, 2005). However, there is considerable evidence that biased 
processing of emotional information also plays a role in the aetiology and maintenance of 
emotional disorders such as depression and anxiety (Leppanen, 2006). The monoamine 
neurotransmitters (serotonin, dopamine and noradrenaline) are known to play a significant 
role in emotional processing and although they are generally considered to act synergistically, 
few studies have specifically investigated interactions between these neurotransmitters.  
 
Serotonin and noradrenaline are also heavily implicated in the aetiology of emotional 
disorders and the majority of therapeutic agents increase synaptic levels of these 
neurotransmitters (Nutt, 2002). Despite their use for over half a century, it remains unclear 
how antidepressants exert their therapeutic effects. More recently, evidence has emerged that 
suggesting that serotonergic and noradrenergic antidepressant drugs may act by modifying 
emotional processing biases (Harmer et al.  2009). Yet in spite of this increasing insight, the 
fact that up to 50% of patients treated with these medications fail to respond adequately to 
remains a significant challenge in the management of these disorders (Souery et al.  1999). 
Inter-individual differences in responses to emotional stimuli may contribute to differences in 
vulnerability to emotional disorders as well as response to therapeutic agents (Hamann and 
Canli, 2004). It is increasingly accepted that genetic factors explain small but significant 
amounts of this variability (Todd et al.  2011).  Thus, polymorphisms in genes involved 
serotonergic and noradrenergic signalling represent apposite candidates for further 
investigation.  
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One of the genetic variants that have been most extensively investigated in relation to human 
emotional processing and emotional disorders is the gene encoding the serotonin transporter 
(5-HTT or SLC6A4). An insertion/deletion polymorphism in the promoter region of this gene 
(5-HTTLPR) results in 2 common allelic variants: short (s) and long (l). The former has been 
associated with reduced transporter transcription, resulting in approximately 50% reduction 
in transporter availability in vitro and presumed increased synaptic serotonin availability 
(Heils et al.  1996). More recently, an additional A/G SNP in the l allele (rs25531) has been 
found to further influence transcriptional activity. The G variant of the l allele is considered 
to result in a reduction in transcriptional efficiency to a level similar to that of the s allele (Hu 
et al.  2005; Wendland et al.  2006). The frequency of this G allele varies with ethnicity 
however it is relatively uncommon in white European ethnic groups (Hu et al.  2006). Early 
seminal studies linked the s allele to increased neurotic personality traits (Lesch et al.  1996) 
and an increased risk of depression in the context of adverse life events (Caspi et al.  2003). 
Subsequent studies examining the in vivo effects of this genetic variation on the phenotypic 
expression of the serotonin transporter in the human brain produced inconsistent results 
(Praschak-Rieder et al.  2007; Reimold et al.  2007; van Dyck et al.  2004; Willeit et al.  
2000). However, consistent with a number of prior studies, a relatively large recent positron 
emission tomography (PET) study in healthy volunteers found that polymorphic variation in 
5-HTTLPR did not alter expression of the serotonin transporter (Murthy et al.  2010). It has 
however been suggested that this genetic variation instead contributes to early 
neurodevelopmental changes that may impact on brain structure and function in later life 
(Lesch and Gutknecht, 2005). This would be consistent with the further body of functional 
magnetic resonance imaging (fMRI) literature that has more consistently documented that s 
allele carriers demonstrate significantly greater amygdala activation in response to aversive, 
relative to neutral, stimuli in a variety of emotional processing tasks (Bertolino et al.  2005; 
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Canli et al.  2005; Hariri et al.  2002; Hariri et al.  2005; Heinz et al.  2004; Pezawas et al.  
2005); for a meta-analysis see (Munafò et al.  2008). Yet, the behavioural implications of 
these neural differences remained unclear. More recently a number of studies have focused 
on ‘behavioural endophenotypes’ such as selective attentional biases for emotional 
information. To date, these studies have demonstrated an association between the 5-HTTLPR 
s allele and preferential attention to aversive stimuli (Beevers et al.  2007; Beevers et al.  
2010; Beevers et al.  2011; Fox et al.  2009; Osinsky et al.  2008). However, these reports 
have not been entirely consistent (Caspi et al.  2010). One important potential source of 
inconsistency and non replication in genetics studies of complex quantitative traits is the 
issue of polygenicity, including biologic epistasis (Moore, 2008). Yet none of these 
neuroimaging or behavioural genetics studies has examined the effects of the other major 
neurotransmitter system implicated in affective spectrum disorders and emotional processing: 
the noradrenergic system.   
 
Noradrenaline has an established role in modulating memory enhancement for emotionally 
arousing information (McGaugh, 2004) and recent pharmacological challenge studies 
indicate that it is also involved in modulating attentional biases for emotional information in 
healthy human volunteers (De Martino et al.  2008). However the contribution of genetically 
influenced differences in noradrenergic tone to inter-individual differences in human 
emotional processing has been largely unexplored. An insertion/deletion polymorphism in the 
alpha 2b adrenergic (auto)receptor gene (ADRA2B) has recently been found to contribute to 
individual differences in emotionally influenced memory processes. The deletion variant 
(Del301-303) is associated with decreased agonist-promoted phosphorylation and receptor 
desensitisation in vitro (Small et al.  2001), presumed to be associated with increased 
noradrenergic tone in vivo. In two seminal studies, de Quervain and colleagues demonstrated 
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an association between this polymorphic variant, increased amygdala reactivity and an 
increased memory bias for emotional stimuli (de Quervain et al.  2007; Rasch et al.  2009). 
However, the contribution of ADRA2B to emotionally enhanced attentional processes was 
not explored. It therefore remains possible that the observed memory bias arises due to an 
attentional advantage contributing to enhanced encoding of emotional information (Todd et 
al.  2011). The purpose of this study was therefore to test the hypothesis that an increased 
attentional bias for emotionally arousing information is associated with the deletion variants 
of ADRA2B and 5-HTTLPR and examine whether these effects are subject to additive or 
non-additive interactions.   
 
Materials and methods 
Participants 
One hundred and seven healthy white British male volunteers between the ages of 18 and 35 
(mean 24.0 ± 4.8) were recruited from the university and local community. They had no 
lifetime history of psychiatric or neurological disorder. Estimates of verbal IQ were derived 
from the National Adult Reading Test (NART) (Nelson, 1982). The study was approved by 
the local research ethics committee. Following complete description of the study to the 
participants, written informed consent was obtained.  
 
 
Behavioural task  
We used an emotional attention blink (AB) task based on dual-target rapid serial visual 
presentation (RSVP) methodology (Raymond et al.  1992). Identification of a 1st target (T1) 
in a rapid stream of stimuli leads to transient impairment in identification of a 2nd target (T2) 
– an effect, known as the attentional blink. It has previously been used by ourselves and 
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others to demonstrate a bias towards accurate detection of aversive T2 targets compared to 
neutral (Anderson, 2005; Anderson and Phelps, 2001; De Martino et al.  2008; Gibbs et al.  
2007; Keil and Ihssen, 2004).  The task comprised 168 trials, each trial consisting of 13 white 
distracter words and 2 green target words (T1 and T2) presented sequentially in the centre of 
a laptop computer screen; see Figure 1. T1 stimuli were all neutral words averaging 4.8 
letters in length. T2 words were derived from the Affective Norms for English Words 
(Bradley and Lawson, 1999) and half were aversive-arousing (mean valence and arousal 
ratings of 2.5 and 7.0, respectively) and half were neutral (mean valence and arousal ratings 
of 5.1 and 3.5, respectively). Aversive and neutral T2 stimuli did not differ significantly in 
letter length (mean = 5.1 vs 4.8, respectively; p=0.21) or written word frequency (mean = 
67.1 vs 87.9, respectively; p=0.50) (Kucera and Francis, 1967). Distracter items were 92 
words of longer length (mean letters = 12.5) to facilitate masking of the targets. Each item 
was presented for 100 milliseconds (ms) and was immediately followed by the subsequent 
item. The lag between the T1 and T2 targets was varied to contain one, three, or five 
intervening distracters (Lag 2, Lag 4 or Lag 6) with corresponding Stimulus Onset 
Asynchronies (SOAs) of 200ms, 400ms or 600ms. Participants were instructed to ignore the 
words in white (distracters) and identify the two green target words (T1 and T2). Responses 
were made by participants writing down the two targets in any order immediately after each 
trial on sheets that were subsequently scored. Exactly correct spelling was not necessary for a 
correct response. Vowel and consonant omissions, insertions or replacements were allowed 
provided the word was recognisable and the spelling was phonologically accurate.  
Figure 1 about here 
 
Genotyping 
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DNA extraction and genotyping for the ADRA2B insertion/deletion polymorphism was 
carried out by KBioscience, Hertfordshire, UK as previously reported (Gibbs et al.  2010). 
For the 5-HTTLPR insertion/deletion, polymerase chain reaction (PCR) was also carried out 
using KBioscience in-house single nucleotide polymorphism (SNP) genotyping system 
(KASPar®)  using fluorescently labelled primers (pF1:Cy5.5-
CCCAGCGTGCTCCAGAAAC; 
pR:GGACCTGGGCAGTTGTGC). For technical reasons, we were unable to complete 
further triallelic genotyping of the A/G SNP (rs25531) in the 5-HTTLPR insertion allele. 
 
Statistical analysis 
Hardy-Weinberg equilibrium (HWE) of genetic data was assessed by χ2 analysis.  Possible 
genotype-dependent differences in demographic variables between genotype groups were 
assessed in a multivariate analysis of variance (ANOVA) with age and IQ as dependent 
variables and 5-HTTLPR and ADRA2B genotypes as between-subjects factors. Genotype 
effects on T1 detection in the AB task were examined in a univariate analysis of variance 
with percent correct T1 report as the dependent measure and 5-HTTLPR and ADRA2B 
genotypes as the between-subjects factors. Affective modulation of the AB effect was 
examined in a repeated measures ANOVA with the same between-subjects factors, valence 
(aversive, neutral) and lag (2, 4 and 6) as within-subject factors and percent correct T2 report 
[contingent on the correct identification of T1]4 as the dependent measure. Significant 
interactions were explored using post hoc t-tests. A Greenhouse-Geisser correction was 
applied where sphericity assumptions were violated. 
 
 
                                                 
4
 This is to guarantee that proper attention has been devoted to T1 to ensure an AB effect. 
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Results 
Genotypes 
Of the 107 participants, ADRA2B genotypes were unavailable for 2 participants, 11 were 
homozygous carriers of the ADRA2B deletion, 48 were heterozygotes and 46 were non 
carriers, consistent with HWE (χ2=0.09, p=0.77). Due to the small number of homozygous 
carriers, they were combined with the heterozygotes, giving two genotype groups of deletion 
carriers (Del) and non carriers (Ins) as previously done by ourselves and others (de Quervain 
et al.  2007; Gibbs et al.  2010). For 5-HTTLPR, 12 genotypes were unavailable, 35 were 
homozygous l/l, 41 were heterozygous s/l and 19 were homozygous s/s, consistent with HWE 
(χ2=1.18, p=0.28). Given that the s allele is considered to have a dominant effect (Lesch et al.  
1996), participants were divided into two groups: homozygous or heterozygous s allele 
carriers (S group) and non carriers (L group) consistent with prior studies (Canli et al.  2005). 
Participants for whom genetic data were not available for both polymorphisms were excluded 
from further analysis, leaving a total sample of 94. Demographic characteristics (age and IQ) 
are given in Table 1. There were no genotype effects on these variables. 
Table 1 about here 
Behavioural data 
There was a significant main effect of valence on T2 detection accuracy [F(1, 90) = 11.0, p = 
0.001], with greater detection of aversive (92.7% ± 1.6) compared to neutral (81.2% ± 1.2) 
words. T2 detection accuracy also increased significantly [F(1.2, 109.4) = 183.3, p < 0.001] 
as the temporal lag between the targets increased [lag 2 = 64.4% ± 22.2; lag 4 = 83.8% ± 
15.7, lag 6 = 91.1% ± 12.3] and there was a significant lag x valence interaction [F(2, 180 = 
28.5, p < 0.001] such that the emotional attentional bias was most pronounced at lag 4 (9%) 
compared to lag 6 (3%) and lag 2 (-3%) where it was absent. There were no main effects of 
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the individual genes however there was a highly significant ADRA2B x 5-HTTLPR x 
valence interaction [F(1, 90) = 15.0, p < 0.001]. In order to clarify this interaction we first 
conducted a separate repeated measures analysis of variance in the 5-HTTLPR S and L 
groups with T2 detection as the dependent variable, valence (aversive, neutral) as the 
between subjects variable and ADRA2B genotype as the between subjects variable. We 
found significant ADRA2B x valence interactions in both 5-HTLPR S [F(1, 58) = 8.2, p = 
0.006] and L [F(1, 32) = 6.06, p = 0.02] groups. Post hoc paired t-tests demonstrated that in 
the 5-HTTLPR L group, there was a significant attentional bias for aversive vs. neutral T2 
words in ADRA2B deletion carriers [t(20) = 3.0, p = 0.007, d = 0.7] that was absent in non 
carriers [t(12) = -0.68, p = 0.504]. Conversely, in the 5-HTTLPR S group, the significant 
emotional attentional bias was absent in ADRA2B deletion carriers [t(29) = 0.477, p = 0.637] 
but present in non carriers [t(29) = 4.9, p < 0.001, d = 1]. See Figure 2. There were no other 
significant main genotype effects or interactions in relation to T1 or T2 detection. 
Figure 2 about here 
 
Discussion 
The purpose of this study was to examine the effects of serotonergic (5-HTTLPR) and 
noradrenergic (ADRA2B) genetic variants on attentional biases for aversive stimuli using an 
attentional blink (AB) paradigm. To our knowledge, this is the first study to examine the 
contribution of the ADRA2B insertion/deletion polymorphism to individual differences in 
emotional attentional biases and only the second study to explore the genetic basis of the 
emotional AB effect - cf., Munafò and colleagues previously found an association between 5-
HTTLPR genotype, smoking status and detection of smoking-related stimuli in an AB task 
(Munafò et al.  2005). The significant novel finding from this study is that the affective 
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modulation of T2 detection is influenced by a non-additive (epistatic) interaction between the 
ADRA2B and 5-HTTLPR insertion/deletion polymorphisms.  
 
Specifically, we found that a significant attentional bias for aversive compared to neutral 
information was present in individuals possessing at least one copy of the short (s) allele of 5-
HTTLPR, but only if they did not carry the ADRA2B deletion. Conversely, the attentional 
bias for emotional information was only present in 5-HTTLPR long (l) allele homozygotes if 
they were ADRA2B deletion carriers. This suggests that in the presence of the 5-HTTLPR s 
allele which is a putative risk allele for depressive and anxiety disorders, the negative 
attentional bias is attenuated by the ADRA2B deletion variant whereas in the absence of the s 
allele, the bias is enhanced. Both of these effects may be related to adaptive processes. For 
instance, dependent on 5-HTTLPR genotype, the effect of the ADRA2B deletion variant may 
be to either exert a protective effect against affective spectrum disorders or facilitate 
enhanced detection of threat, in both cases contributing to increased probability of survival.  
 
Behavioural genetics implications 
We did not find a main effect of the serotonin transporter polymorphism on emotional 
attention as a number of prior studies have done (Beevers et al.  2007; Fox et al.  2009; 
Munafò et al.  2005; Osinsky et al.  2008). However, with the exception of Munafò et al 
2005, all of these studies have used a variation of the dot probe task to evaluate emotional 
biases in selective attention, rather than the AB task. Although both of these tasks evaluate 
selective attention when cognitive resources are limited, the latter measures deployment of 
attention resources under temporal constrains whilst the former typically utilises spatial 
limitations. Notably, Munafò et al 2005 also used a alternate variant of the AB task that 
indexes attention by establishing whether the detection of a neutral T2 target is impaired a 
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preceding emotionally salient or neutral T1 target. It is possible that these task-related 
differences may account for the difference in findings. Yet the studies reporting positive 
associations using the dot probe task are not without inconsistencies. For example some have 
linked the s allele to biases toward aversive stimuli (Beevers et al.  2007; Osinsky et al.  
2008) whilst others suggest that the l allele results in biases away from negative stimuli (Fox 
et al.  2009; Kwang et al.  2010). Other discrepancies include 5-HTTLPR associations found 
only with long (Osinsky et al.  2008) or short (Beevers et al.  2007) stimulus presentation 
durations. In spite of using shared dot probe methodology, there are still been significant 
differences between these studies in terms of subjects (healthy volunteers vs psychiatric 
patients; men vs women), stimuli (words vs spiders vs pictorial scenes) and duration of 
stimulus presentation (<500ms vs > 500ms). These differences highlight the need for task 
consistency in future studies in order to facilitate replication (NCI-NHGRI Working Group 
on Replication in Association Studies, 2007).  
 
The effect of the ADRA2B insertion/deletion polymorphism on attentional biases for 
emotional information has not been previously investigated. However it has been suggested 
that it might contribute to the emotional memory bias observed in ADRA2B deletion carriers 
(Todd and Anderson, 2009). We did not find any main effect of ADRA2B on emotional 
attention in this study suggesting that the ADRA2B deletion variant does not independently 
bias attention towards emotional stimuli but may interact with other monaminergic gene 
systems to contribute to such bias.  
 
Behavioural pharmacogenetics implications 
A number of studies have begun to examine possible interactions between 5-HTTLPR 
polymorphisms, emotional attentional biases and the effects of serotonergic manipulation by 
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acute tryptophan depletion (ATD) but have thus far failed to produce consistent findings 
(Firk and Markus, 2009; Markus and De Raedt, 2011; Markus and Firk, 2009; Roiser et al.  
2007). This may in part be due to the fact that ATD in healthy volunteers, independent of 
genotype, has not produced entirely consistent effects on emotional processing (Hayward et 
al.  2005; Murphy et al.  2002; Rubinsztein et al.  2001). No studies have as yet examined the 
possible contribution of genetic variation to the effects of serotonergic and noradrenergic 
drugs on emotional attention. However, a number of pharmacological studies have examined 
the effects of serotonergic and noradrenergic drugs on emotional processing in healthy 
subjects (Arce et al.  2008; Arnone et al.  2009; Brühl et al.  2009; Harmer et al.  2008; 
Harmer et al.  2003; Harmer et al.  2004; Murphy et al.  2009a; Norbury et al.  2007; 
Rawlings et al.  2010). This work may be relevant to understanding the present findings 
however it is difficult to make direct comparisons between genetically and pharmacologically 
mediated effects on emotional processing as highlighted in the Clinical Implications below. 
Additionally, only three of these studies have specifically examined attentional biases and 
have produced relatively inconsistent findings (Browning et al.  2007; De Martino et al.  
2008; Murphy et al.  2009b).  
 
Using a dot probe task, Browning et al 2007 found that the administration of a single dose of 
the selective serotonin reuptake inhibitor (SSRI) antidepressant citalopram to healthy 
volunteers resulted in an attentional bias towards positive words (Browning et al.  2007). This 
is consistent with some of the behavioural findings in relation to the 5-HTTLPR l allele 
described above. On an AB task, De Martino et al found that a single dose of the 
noradrenaline reuptake inhibitor (NRI) reboxetine boosted detection of emotionally arousing 
compared to neutral words in healthy volunteers (De Martino et al.  2008). Also on a dot 
probe task in healthy volunteers, Murphy et al 2009 found that repeated citalopram 
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administration reduced the attentional bias towards emotional faces, independently of 
valence, whilst reboxetine had no effect (Murphy et al.  2009b). These apparently conflicting 
findings could again be related to differences in methodology (dot probe vs. AB; words vs. 
faces; single vs. repeated dosing). In fact, there is evidence from both animal and human 
studies that acute and chronic citalopram administration may differentially influence 
emotional processing such that acute doses result in an intial increase in the processing of 
negative information that is attenuated with repeated dosing (Burghardt et al.  2004; Harmer 
et al.  2003; Harmer et al.  2004). However genotype-dependent drug effects may also 
contribute to these differences. For example, pharmacological enhancement or attenuation of 
emotional attentional biases may be less prominent in individuals with genotype-related 
emotional processing biases or in whom such biases are absent, respectively. If emotional 
attentional bias is to function as an effective cognitive marker, future pharmacological 
challenge studies will also need to consider the contribution of genetic variations in the 
neurotransmitter systems under investigation. There is also an increasing need to evaluate the 
effects of genetic epistasis between these systems as this may have important clinical 
implications for the pharmacogenetics of depression and anxiety. 
  
Clinical implications 
That such biological epistasis exists between serotonergic and noradrenergic genes, is 
consistent with the fact that these neurotransmitter systems are intimately connected in the 
central nervous system (de Boer, 1995). Noradrenergic neurotransmission is modulated by 
presynaptic inhibitory alpha 2 adrenergic (auto)receptors and their blockade increases 
synaptic levels of noradrenaline. However there is evidence that serotonergic 
neurotransmission is also modulated by presynaptic alpha 2 adrenergic (hetero)receptors 
(Clement et al.  1992; De Boer et al.  1994; Mongeau et al.  1993). Yet precisely how these 
Naudts KH, et al, 2012, Int. J. Neuropsychopharm, 15(8): 1027-1036 
 
 84 
systems may interact to produce the intermediate phenotypes and the clinical disorders 
themselves remains unclear. The fact that the majority of drugs used to treat affective 
spectrum disorders act by inhibiting the serotonin transporter seems at odds with the fact that 
individuals with genetically influenced reductions in serotonin transporter function have 
greater risks of developing these disorders, as well as poorer treatment response rates (Lesch 
and Gutknecht, 2005). This ostensible contradiction is increasingly understood in terms of the 
complex autoregulatory processes governing serotonergic function (Routledge and 
Middlemiss, 1996) and the potentially deleterious neurodevelopmental effects of excessive 
intra-synaptic accumulation of serotonin (Lesch and Gutknecht, 2005). Via its intimate 
relationship with serotonergic signalling, the ADRA2B polymorphism may also exert its 
epistatic effects via these autoregulatory and neurodevelopmental mechanisms. 
 
Whilst this hypothesis warrants further investigation, the biological epistasis suggested in the 
present study may have important implications for individual responses to serotonergic and 
noradrenergic antidepressant drugs. The vast majority of pharmacogenetics studies in 
depression have focussed on variations in the serotonin transporter (Schosser and Kasper, 
2009; Serretti et al.  2007). However two large recent projects (STAR*D and GENDEP) have 
found associations between antidepressant response and  a number of candidate genes 
involved in both serotonin and noradrenaline signalling (Hu et al.  2007; McMahon et al.  
2006; Paddock et al.  2007; Uher et al.  2009), although none of these studies included the 
ADRA2B polymorphism. The GENDEP project did examine a polymorphism in the related 
ADRA2A gene encoding alpha 2A adrenoceptor subtype but failed to find any significant 
effect despite a previously reported association with the response to the serotonin-
noradrenaline reuptake inhibitor milnacipran (Wakeno et al.  2008). Of note, neither of the 
two antidepressant evaluated in GENDEP was a molecular target of the alpha 2 adrenoceptor 
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group.  Thus, the role of polymorphic variation in alpha 2 adrenergic receptors (and their 
interaction with serotonergic targets) in the therapeutic response of patients with affective 
spectrum disorders warrants further investigation.  
 
Study limitations  
The purpose of this study was to investigate epistatic effects of serotonergic and 
noradrenergic genes on emotional attentional biases. However, the fact that we measured 
only two polymorphisms out of a number that might contribute to the behavioural effect of 
interest represents a limitation to this study. Most significantly, we were unable to genotype  
the additional rs25531 SNP in the long allele of the serotonin transporter gene. However, 
given that the prevalence of the LG allele is low (approximately 10%), this is unlikely to have 
significantly biased our findings. A further limitation is that although the overall sample size 
was reasonable, there were relatively few individuals in some genotype combinations. This is 
a particular difficulty inherent to measuring epistatic gene effects (Moore, 2008). Future 
studies will need to use large sample sizes and evolving methodologies to effectively evaluate 
the likely effects on emotional processing of multiple gene interactions (Cordell, 2009). The 
final limitation is that we only used aversive stimuli and male volunteers only. While the 
latter eliminated possible biases associated with gender differences in emotional processing, 
it limits the generalisability of our findings. It is therefore unclear whether the observed 
biases are valence and/or gender specific. Additionally the aversive stimuli used included 
range of negative emotions (disgust, fear, sadness) rather than specifically dysphoric or 
threat-related emotions. It is therefore unclear how these processing biases might map onto 
those considered to relate to depression and anxiety disorders. Further studies with larger 
sample sizes including men and women will be required to replicate and extend our findings.  
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Conclusions 
In spite of these limitations, this study begins to contribute to the understanding of multiple 
gene effects and interactions in an established cognitive marker for affective spectrum 
disorders – the negative attentional bias. It further underlines the potential utility of adopting 
the ‘endophenotype’ approach in pharmacogenetics studies, i.e., examing the genetic factors 
underlying not only the clinical response but responses in cognitive and neural markers also. 
One significant challenge for such studies will be to delineate the interaction between 
potential neurodevelopmental effects of genetic polymorphisms influencing brain 
neurotransmitter systems and the acute/sub-acute effects of drug administration. Knockout 
and transgenic mouse models are likely to be useful in appreciating the dynamics of the 
behavioural-psychopharmacogenetic-neurodevelopmental interface. 
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Tables 
Table 1 – Demographic characteristics for 5-HTTLPR and ADRA2B genotypes 
 
 5-HTTLPR ADRA2B 
 S L F p Del Ins F p 
Number of participants 34 60 - - 51 43 - - 
Age [yrs, mean (SD)] 23.9 
(4.9) 
23.9 
(4.3) 
0.02 
- 
0.88 
- 
24.7 
(4.9) 
23.0 
(4.3) 
1.18 
- 
0.31 
- 
IQ [mean (SD)] 105.9 
(6.5) 
104.4 
(7.0) 
2.28 
- 
0.14 
- 
106.7 
(5.7) 
104.7 
(6.4) 
3.01 
- 
0.06 
- 
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Figures (titles and legends) 
Figure 1  
Title: Schematic Representation of Attentional Blink Task 
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Figure 2 
Title: Accuracy (percent correct) of T2 Detection in 5-HTTLPR and ADRA2B Groups 
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Discussion of Thesis  
 
Summary of key findings 
 
The aim of this thesis was to examine the effects of three genetic polymorphisms (COMT 
val158met, 5-HTTLPR S/L and ADRA2B insertion/deletion) on emotional processing in healthy 
volunteers. It was hypothesised that the variants of these genes that have been associated with 
increased monoamine levels (specifically the COMT met158, 5-HTTLPR S, ADRA2B Del and 
MAOA L alleles) would be associated with increased attentional and memory biases for 
emotional, relative to neutral information whilst the alternate alleles would be associated with 
reduced emotional processing biases. This thesis comprises three peer-reviewed publications 
reporting the following key findings. 
Article 1. Deletion variant of α2b-adrenergic receptor moderates the effect 
of COMT val158met polymorphism on episodic memory performance 
(Gibbs et al.  2010) 
The key finding reported in this article was an interaction between the COMT val158met and 
ADRA2B deletion polymorphisms in relation to memory performance, independent of valence. 
Abolition of the relative episodic memory impairment in COMT val/val individuals by 
possession of the ADRA2B deletion variant was observed. No main effects of either 
polymorphism were observed. However this is the first demonstration of an effect of ADRA2B 
genotype on episodic memory performance and its interaction with COMT and suggests that 
genes that do not exert direct effects on cognition might do so indirectly via gene-gene 
interactions. The absence of any gene x emotion interaction suggested that the hypotheses 
relating to the genetic modulation of emotional processing were not confirmed. Prior studies 
demonstrating behavioural effects of the ADRA2B polymorphism on emotional memory have 
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used free recall testing rather than recognition as used in this case. It is therefore possible that the 
failure to demonstrate this effect relates to this difference in approach to the evaluation of 
memory performance. Under the dual-process signal detection (DPSD) model, recognition 
memory is considered to comprise two distinct processes: recollection and familiarity (Yonelinas, 
2002). The latter is considered to be a quantitative, memory-strength based process, associated 
with a “sense of having previously seen”. By contrast, recollection is presumed to be a qualitative 
threshold process, associated with high levels of contextual detail and high confidence 
judgements, and is considered most closely related to recall performance (Mandler, 1980). This 
model was therefore applied to the recognition memory data in order to examine whether any 
gene x emotion interactions might be elicited in relation to the recollection component. The 
results of this further analysis are reported in Article 2. 
 
Article 2. Influence of COMT val158met and ADRA2B deletion 
polymorphisms on recollection and familiarity components of human 
emotional memory (Naudts et al.  2012a) 
The key finding reported in this article is a significant effect of COMT genotype on the emotional 
memory bias with respect to the recollection, but not familiarity, component. Specifically, 
recollection was significantly greater for emotionally arousing vs. neutral pictures in carriers of 
the val158 allele compared to met158 carriers. This is the first reported finding of an effect the 
COMT val158met polymorphism on memory biases for emotional information. However, in 
contrast to previous studies, there was still no evidence of an effect of ADRA2B on emotional 
memory biases in relation to recollection or familiarity processes. This may have been due to 
inadequate statistical power. However, methodological differences other than recall vs. 
recognition may have been relevant. For example, in the present study, a 1 week interval between 
encoding and memory testing was used, as opposed the short 10 minute retention interval in prior 
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studies. It is possible that the ADRA2B-dependent differences observed by others relate to 
encoding processes, such as attention and perception, influencing short-term memory, as opposed 
to the consolidation processes contributing to long-term memory. This would be consistent with 
the functional neuroimaging findings in which ADRA2B genotype-dependent differences in 
amygdala activation observed during encoding emotional vs. neutral stimuli did not influence 
subsequent memory (Rasch et al.  2009), although this was attributed by the authors to 
inadequate statistical power to detect behavioural differences. Given that memory was tested at a 
single time point in their study and the present study, this issue remains unresolved. Further 
studies will be necessary to clarify the effects of ADRA2B on the affective modulation of 
attention/perception during encoding and the effects of post-encoding arousal (Todd et al.  2011). 
However, the findings in relation to the genotype dependent effects of attentional biases for 
emotional stimuli using the attentional blink task may be helpful in this respect. These results are 
reported in Article 3 below.   
 
Article 3. Epistasis between 5-HTTLPR and ADRA2B polymorphisms 
influences attentional bias for emotional information in healthy volunteers 
(Naudts et al.  2012b)  
This article reports evidence of a significant epistatic effect between the 5-HTTLPR and 
ADRA2B insertion/deletion polymorphisms on attentional biases for emotional information 
using the attentional blink task. Specifically, the attentional bias for aversive information 
observed in association with the 5-HTTLPR S allele was attenuated by possession of the 
ADRA2B deletion variant, whereas in the absence of the S allele, the bias was enhanced by 
possession of the ADRA2B deletion variant.  This is the first study to examine the contribution of 
the ADRA2B insertion/deletion polymorphism to individual differences in emotional attentional 
biases and only the second study to explore the genetic basis of the emotional AB effect - cf., 
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Munafò and colleagues previously found an association between 5-HTTLPR genotype, smoking 
status and detection of smoking-related stimuli in an AB task (Munafò et al.  2005). The present 
data identify a cognitive mechanism linking genotype-dependent serotonergic and noradrenergic 
signalling that may have implications for the development of cognitive markers for affective 
spectrum disorders as well as therapeutic drug effects and personalised approaches to treatment. 
 
One limitation of the findings reported in this article is that it was not possible to genotype an 
additional A/G SNP (rs25531) in the long allele of the serotonin transporter gene that has 
recently been described. This SNP has been found to further influence transcriptional activity 
such that the G variant of the l allele is considered to result in a reduction in transcriptional 
efficiency to a level similar to that of the s allele (Hu et al.  2005; Wendland et al.  2006). The 
frequency of this G allele varies with ethnicity however it is relatively uncommon in white 
European ethnic groups (Hu et al.  2006). It is therefore unlikely to have significantly biased our 
findings. 
 
Implications of findings 
Taken together, these findings contribute to increased understanding of the neurobiology of 
cognitive and emotional processing, specifically the contribution of genetic variation to 
individual differences in these processes. In addition to the implications for each finding, 
discussed in the relevant articles, as a whole, this thesis provides evidence to support the 
hypothesis that biological epistasis is central to the effect of genetic variation on individual 
differences in cognitive and emotional processing. It delineates two such examples. This is 
relevant because failure to take these interactions into account in future studies may obscure 
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effects and contribute to null findings. Such interactions may also provide pointers towards more 
individualised, and therefore potentially more effective, pharmacological interventions. 
 
For example, the finding that the cognitive disadvantage associated with COMT val158 allele 
carriage may be ameliorated by possession of the ADRA2B deletion variant suggests that 
pharmacological interventions that approximate the neurochemical effects of possession of this 
variant could be particularly beneficial in the enhancement of cognition in COMT val/val 
individuals. Although conducted in healthy volunteers, this has relevant clinical implications. 
Cognitive dysfunction is a highly disabling feature of a number of neuropsychiatric disorders 
including schizophrenia, bipolar affective disorder, depression and attention deficit hyperactivity 
disorder (ADHD). Developing disease-modifying and symptomatic therapies for cognitive 
dysfunction is therefore a major goal of drug development (Searles et al.  2008).  However drug 
development, particularly central nervous system (CNS) drug development, requires substantial 
investment, with development costs estimated at over $1 billion USD, a timeline of over 10-15 
years and success rates as low as 5-10% (Kola and Landis, 2004). Population segmentation or 
personalised medicine, i.e. the use of pharmacogenomics and other biomarkers of mechanism to 
identify individuals most likely to respond, are increasingly considered crucial to drug 
development strategies to enhance success rates (Wang, 2010). 
 
Such approaches to enhancing cognition have already been demonstrated with the COMT 
enzyme inhibitor tolcapone. In the first study to demonstrate these effects in humans, Apud and 
colleagues found a significant drug x genotype interaction on episodic memory performance, 
such that tolcapone enhanced performanced  in val/val genotypes whereas performance in 
met/met genotypes worsened. (Apud et al.  2007). fMRI revealed a significant tolcapone-induced 
improvement in the efficiency of information processing in the prefrontal cortex during a 
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working memory test in val/val individuals. These genotype-dependent effects of tolcapone have 
since been replicated in relation to working memory (Farrell et al.  2012).  It has been suggested 
that these differential effects are linked the inverted U shaped curve relationship between pre-
frontal catecholamine levels whereby not only too little, but also too much, may impair PFC 
function. Under this relationship, tolcapone administration shifts val/val individuals up the curve 
to a more advantageous position of catecholamine levels and PFC function, whilst pushing 
met/met individuals down the curve to a more disadvantageous position.  
 
COMT is not considered to play a major role in modulating noradrenergic neurotransmission in 
the PFC however noradrenaline is also crucial to PFC cognitive function and has therefore also 
represented a target for clinical enhancement of cognitive function (Arnsten, 2004; Nutt et al.  
1997). However, four recent studies investigating the effect of two noradrenaline reuptake 
inhibitors, atomoxetine and reboxetine, on cognitive impairment in patients with schizophrenia 
failed to demonstrate any consistent beneficial effect (Friedman et al.  2008; Kelly et al.  2009; 
Poyurovsky et al.  2009; Sacco et al.  2009). These inconclusive findings may be due to the fact 
that all of these studies were small, with participant numbers ranging from 12 to 33, and therefore 
likely to have been underpowered. However, genotype dependent effects may also have 
contributed to this inconsistency in a number of ways. This thesis suggests that increased PFC 
noradrenaline levels as a result of possession the ADRA2B deletion variant may compensate for 
reduced dopamine levels in COMT val/val individuals. Clinical trials examining the effect of 
atomoxetine on cognitive dysfunction in healthy individuals and patients with schizophrenia 
based on COMT genotype are already under way (www.clinicaltrials.gov). However the findings 
reported in Article 1 of this thesis suggest that such genotype-dependent therapeutic drug effects 
may be dependent on both COMT and ADRA2B genotypes. For example, noradrenaline reuptake 
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inhibitors may be most effect in treating cognitive dysfunction in COMT val/val individuals who 
do not possess the ADRA2B deletion variant.  
 
 
The findings from Article 3 further support this approach in the treatment of depression (Naudts 
et al.  2012b). These findings suggest that the attentional bias for aversive information observed 
in association with the 5-HTTLPR S allele, known to be associated with genesis and maintenance 
of depressive symptoms, was attenuated by possession of the ADRA2B deletion variant. 
Conversely, in the absence of the S allele, the bias was enhanced by possession of the ADRA2B 
deletion variant.  
 
That such biological epistasis exists between serotonergic and noradrenergic genes, is consistent 
with the fact that these neurotransmitter systems are intimately connected in the central nervous 
system (de Boer, 1995). There is evidence that presynaptic inhibitory α2 adrenergic receptors are 
not only involved in the modulation of noradrenergic neurotransmission, but also serotonergic 
transmission presynaptic heteroreceptors (Clement et al.  1992; De Boer et al.  1994; Mongeau et 
al.  1993). Yet precisely how these systems may interact to produce the intermediate phenotypes 
and the clinical disorders themselves remains unclear. The fact that the majority of drugs used to 
treat affective spectrum disorders act by inhibiting the serotonin transporter seems at odds with 
the fact that individuals with genetically influenced reductions in serotonin transporter function 
have greater risks of developing these disorders, as well as poorer treatment response rates (Lesch 
and Gutknecht, 2005). This ostensible contradiction is increasingly understood in terms of the 
complex autoregulatory processes governing serotonergic function (Routledge and Middlemiss, 
1996) and the potentially deleterious neurodevelopmental effects of excessive intra-synaptic 
accumulation of serotonin (Lesch and Gutknecht, 2005). Via its intimate relationship with 
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serotonergic signalling, the ADRA2B polymorphism may also exert its epistatic effects via these 
autoregulatory and neurodevelopmental mechanisms. 
 
Furthermore, it is widely perceived in clinical practice that certain patients are more likely to 
benefit from noradrenergic, as opposed to serotonergic, antidepressants than others. The 
mechanisms underlying this effect are not known although it does not appear to be attributable to 
severity (Wiles et al.  2011).  However, the established role of noradrenaline in the 
pathophysiology of depression led to the development of a number of antagonists of the α2 
adrenergic receptor aimed at increasing noradrenaline levels by disrupting feedback mechanisms. 
These compounds all failed in clinical trials for depression in the 1980s. Furthermore, despite its 
approval for the treatment of depression in Europe, the efficacy of the noradrenaline reuptake 
inhibitor reboxetine as an antidepressant has been called into question and indeed in the USA the 
application was rejected after an initial preliminary approval (Dirk et al.  2010; Page, 2003). It is 
possible that the genetic polymorphisms in noradrenergic genes may contribute to these 
inconsistencies.. The vast majority of pharmacogenetics studies in depression have focussed on 
variations in the serotonin transporter (Schosser and Kasper, 2009; Serretti et al.  2007). However 
recent studies suggest that variations in the noradrenaline transporter gene may predict response 
noradrenaline reuptake inhibitors (Hu et al.  2007; McMahon et al.  2006; Paddock et al.  2007; 
Uher et al.  2009). Thus, variation in the α2 adrenergic receptor genes may also be relevant. 
However, the two studies investigating the ADRA2A gene encoding α2A adrenoceptor subtype 
have produced conflicting reports (Wakeno et al.  2008).  
 
The findings reported in Article 3 also suggest that epistatic effects may be more important in 
mediating the therapeutic response to both psychological and pharmacological treatments for 
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depression. Figure 1 below illustrates how these effects might theoretically be used in a 
personalised approach to the treatment of depression. Such hypothesis-driven population 
segmentation approaches to are likely to enhance success of clinical trials however their 
incorporation into pharmacogenomics studies remains in its infancy. 
Figure 1 - Example of how cognitive marker- and genotype-based treatments may be 
applied for affective spectrum disorders 
 
Patients A and C have different 5-HTTLPR genotypes but both have the ADRA2B 
insertion variant associated with enhanced agonist-mediated down-regulation of 
monoamine levels. Therefore an alpha 2 adrenergic antagonist may augment, and 
potentially hasten the therapeutic efficacy of SSRI/SNRI treatment by blocking normal 
inhibitory feedback mechanisms. Patient A has the 5-HTTLPR L genotype associated with 
enhanced response to therapeutic drug treatment and no cognitive bias therefore 
psychotherapy may not offer additional benefits. However Patient C has the 5-HTTLPR S 
genotype associated with poor treatment response and a cognitive bias that may benefit 
from adjunctive psychotherapy. Patients B and D both have the ADRA2B deletion variant 
associated with reduced agonist-mediated down-regulation of monoamine levels and 
therefore possess a genotype-related constraint on inhibitory feedback mechanisms. Thus, 
alpha 2 adrenergic antagonist augmentation is not warranted. However Patient B possesses 
a cognitive bias that may benefit from psychotherapeutic intervention. This algorithm 
remains speculative but provides an initial example of how the effects of genetic variations 
and epistatic interactions may guide therapeutic decision-making. 
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Limitations of thesis and future work 
 
The studies conducted as part of this thesis have produced preliminary published findings 
supporting potentially clinically relevant epistatic effects. However, there are a number of 
potentially relevant unpublished results that need to be considered. Due to the high failure rate for 
MAOA genotyping, it was not possible to include this polymorphism in the analysis hence this 
polymorphism is not included in the published data. The inclusion of BDNF val66met genotype 
as a covariate did not alter any main effects or interactions hence it was not reported on. All three 
candidate genes (COMT, ADRA2B and 5-HTTLPR) were included in the planned ANOVAs for 
both emotional memory and attentional blink tasks however no statistically significant 3-way 
epistatic interactions emerged. It is possible that the detection of such effects between all three 
candidate genes in a single analysis would have been hampered by the small sample size and 
consequent lack of statistical power. However, significant or near-significant 2-way epistatic 
interactions were observed for episodic memory (COMT x ADRA2B, p = 0.144) and attentional 
bias (5-HTTLPR x ADRA2B, p < 0.001). We therefore chose to focus the analysis and three 
publications exclusively around these specific 2-way gene-gene interactions for memory and 
attention.  
 
Further work to replicate and extend these findings is required. A larger sample and additional 
methodology may be required to fully address the issue of epistasis. For example, the traditional 
parametric statistical linear regression method used in the present studies is not suitable for 
epistasis due to the potential sparseness of the data, i.e., the high number of multilocus genotype 
combinations that have few or no data points and as each additional polymorphism is considered, 
the number of multilocus genotype combinations goes up exponentially such that exponentially 
larger sample sizes are needed to have enough data to estimate the interaction effects (Moore, 
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2008). This leads to reduced power and increased type I and II errors. A number of alternative 
approaches to analysis of genetic epistasis have been developed as a result. One such approach is 
the restriction partition method (RPM) (Culverhouse et al.  2004). An initial step might be to use 
this approach in the present dataset to improve estimation of the sample size required.  
 
Finally, whilst one advantage of the candidate gene approach used in the present investigation is 
that it is hypothesis driven, the pilot nature of the study and the limited resources, resulted in the 
restriction of the investigation to four polymorphisms relevant to the hypotheses of interest. A 
number of additional potentially relevant genetic variants have not yet been investigated in 
relation to emotional processing. As there is therefore no existing evidence of a link to emotional 
processing, they fell outside the scope of this study. For example, genetic variants involved in 
catecholamine reuptake mechanisms (such as the noradrenaline and dopamine transporters) and 
dopamine and serotonin receptors were not investigated. Similarly, other known functional 
polymorphisms affecting adrenergic receptors including the α2 adrenergic receptor subtypes A 
and C were also not included. These and other genes are likely to be involved in the complex 
traits under investigation. Emerging hypothesis-free strategies such as Genome Wide Association 
Studies (GWAS) may be used to address this limitation in future studies however this approach 
typically necessitates even larger sample sizes and remains impractical for the detection of 
higher-order (beyond 2-way) interactions such as the 4-way interactions intended to be examined 
in this study. Therefore the most effective use of GWAS approaches would be in the full 
characterisation of single gene effects that can be used in large scale, suitably powered, candidate 
gene studies to determine hypothesis-driven higher order interactions. Nevertheless, in spite of 
these limitations, this thesis lays the foundations for an approach to investigating genetically 
determined interactions in neurotransmitter systems influencing emotional processing that may 
also have implications for vulnerability to affective disorders and antidepressant response.  
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Appendix I 
Medical history checklist 
 
 
Before you take part in the study we need to know whether you have had any physical or mental 
health problems. Your responses will be strictly confidential. 
 
 
1. Have you ever attended a hospital out-patient appointment? YES  NO 
 
If yes, specify problem:…………………………………………. 
 
 
2. Have you ever been admitted to hospital?    YES  NO 
 
If yes, specify problem:…………………………………………. 
 
 
3. Do you suffer from any mental health/brain disorder?  YES  NO 
o Depression     
o Anxiety 
o Psychosis 
o Mania 
o Epilepsy 
o Other: ……………………………………………. 
 
 
4. Do you regularly use any illicit drugs?     YES  NO 
 
 
5. Have you had an alcohol or drug addiction problem in the past? YES  NO 
 
 
6. Do you smoke cigarettes?      YES  NO 
 
If yes, how many:  ………………………………per day 
 
 
7. Do you take any regular medication?     YES  NO 
 
If yes, specify:  …………………………………………….. 
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Summary 
It is increasingly recognised that inter-individual variation in responses to emotional stimuli 
may contribute not only to differences in vulnerability (and resilience) to emotional disorders, 
but also response to therapeutic agents. Evidence to date suggests that the genes involved in 
monaminergic neurotransmission (5-HTTLPR, ADRA2B, MAOA and COMT) contribute to 
differences in emotional processing in healthy individuals. However, little is known about 
how the different variants of these genes might interact in exerting their effects on emotional 
processing. The studies reported in this thesis used cognitive tasks tapping into attentional 
and memory biases for emotional information to examine the contribution of these genes (and 
their interactions) to emotional processing in healthy individuals. Evidence was found for 
interactions between COMT and ADRA2B in predicting episodic memory performance and 
between 5-HTTLPR and ADRA2B in predicting attentional biases for emotional information. 
These findings warrant further investigation however they contribute to improved 
understanding of the interplay between monoaminergic genetic variants in emotional 
processing which may have implications for pharmacological approaches to treating 
cognitive dysfunction and emotional disorders. 
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Samenvatting 
Het wordt in toenemende mate erkend dat de inter-individuele variatie in respons tot 
emotionele stimuli lijkt bij te dragen tot verschillen in kwetsbaarheid (en weerstand) voor 
emotionele stoornissen en therapeutische respons. Onderzoek wijst er op dat de genen die 
betrokken zijn in mono-aminerge neurotransmissie (5-HTTLPR, ADRA2B, MAOA and 
COMT) bijdragen tot verschillen in emotional processing in gezonde personen. Het is echter 
niet goed gekend hoe de verschillende varianten van deze genen interageren in de uitoefening 
van hun effect op emotional processing. In dit doctoraat gebruikten we cognitieve taken voor 
aandachts- en geheugenbiases voor emotionele informatie om de bijdrage van deze genen en 
hun potentiele interacties in emotional processing verder te onderzoeken. In onze groep 
gezonde vrijwilligers, vonden we interacties tussen COMT en ADRA-2B met effect op 
episodisch geheugen en interacties tussen 5-HTTPLR en ADRA-2B met effect op 
aandachtbiases voor emotionele informatie. Deze bevindingen behoeven verder onderzoek, 
maar ze dragen toe tot een verbeterd begrijpen van de rol van en interacties tussen de 
verscheidene genen en hun varianten in emotional processing. Op lange termijn heeft dit 
mogelijks implicaties voor de pharmacologische behandeling van cognitief dysfunctioneren 
en emotionele stoornissen.  
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Other international experience includes: 
 
Maudsley Forum (annual IoP course for European psychiatrists): I participated in the planning and 
implementation.(2004-2006). I am particularly proud of obtaining funding from the Psychiatry 
Research Trust for several three-month placements at the IoP for colleagues from Central and 
Eastern Europe (2006) 
 
Instigator research and teaching collaboration State Mental Hospital Minsk (Belarus) (2006) 
 
Collaborator in Rus-Nor forensic psychiatry network (Russia-Norway) (2006) 
 
Humanizing Prison Mental Health and Forensic Psychiatric Systems in Georgia (former USSR). Project 
Proposal 2005-2007. Geneva Initiative on Psychiatry 
 
Instigator research collaboration on First Episode Psychosis with Lisbon University (Portugal) (2005) 
 
Human Rights Monitoring Visit for MDAC (Mental Disability Advocacy Centre – Budapest (Hungary) 
and consultancy for MDAC project in Estonia (2004-2005) 
 
European Federation of Psychiatric Trainees: throughout clinical training I was an active board 
member of this organisation (1998-2003) 
 
 
MISCELLANEOUS 
 
I am passionate about current affairs, literature and theatre.  
 
 
 
